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SUMMARY 
 
Dengue virus (DENV) NS3 protease (NS3pro) is essential for viral 
polyprotein processing, a critical component of viral replication. NS3pro is a 
serine protease and comprises the N-terminal 168 amino acids of the 618 
amino acid long full-length NS3 protein. Forty-seven amino acid residues 
from the central hydrophilic region of the NS2B protein form an essential 
cofactor (NS2B47) and must associate with NS3pro to retain its structure and 
maintain enzymatic activity. 
The structure of a single-chain construct of DENV NS3pro joined to 
NS2B47 (NS2B47NS3pro) through a flexible, nonapeptide linker has been 
solved to high resolution in an open conformation, with the C-terminal region 
of NS2B47 folded away from the active site of the protease. The structure of 
West Nile Virus (WNV) NS2B47NS3pro, however, has been solved in both an 
open conformation and with an inhibitor bound in a closed conformation, 
where the C-terminal region of NS2B47 protein wraps around NS3pro and 
folds inward to form part of the NS3pro active site.  An atomic structure of 
DENV NS3pro in the closed conformation would be valuable for gaining 
insight into specific active site residues and for developing anti-viral 
inhibitors.  
A four amino acid turn, located from amino acid residues 29 to 32 in 
NS3pro, protrudes from the protein surface. Consisting of two central, 
hydrophobic residues with single Gly residues flanking each side, the turn 
(HT29-32) is believed to be involved in membrane association, and full-length 
NS3 with 18 central amino acid residues from NS2B was shown to associate 
with a liposome surface using Surface Plasmon Resonance (SPR) biosensing 
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(Luo et al., 2010). In this study, NS2B47NS3pro constructs were generated 
with the two, central amino acids of HT29-32 mutated to either two Ala 
residues or two Ser residues for all four DENV serotypes. Utilizing several 
biochemical techniques, the mutant proteins were shown to retain similar 
structural and functional characteristics in general compared to the wild-type 
(WT) proteins, though the WT proteins exhibited variation between serotype. 
Protein crystallization experiments for DENV 2 serotype proteases led to 
crystals for DENV 2 WT but not for the mutants, suggesting that changes 
HT29-32 prevent crystal formation.  
HT29-32 was shown to associate with a liposome surface within the 
context of DENV 4 NS2B18NS3 full-length protein in the study by Luo et al 
(2010). Similarly, in this study, the DENV 2 NS2B47NS3pro was shown to 
interact with a lipsosome surface using SPR technology. The mutations caused 
a reduction in the level of lipid association. SPR was also tested as a high 
throughput method of screening inhibitors for DENV NS3pro while the 
protein is bound to a liposome surface. A binding curve for aprotinin, a 
ubiquitous protease inhibitor, was clearly visualized using this technique. 
Because SPR lipid testing is time and labor intensive, however, it is unlikely 
to be used for high throughput screening in the future. It could, however, be 
developed into a secondary screen to verify high throughput hits.  
This work contributes to the structural understanding of DENV 
NS3pro. The performed studies indicate the continued need for further 
investigation. 
 
 
 
IX 
 
LIST OF TABLES 
Table Page 
1 NS3 protease percent identity matrix.......................................................... 18 
2.1 Primers for mutagenesis.............................................................................. 32 
2.2 Bacterial growth medium (Total composition in 1 L)................................ 34 
3.1 Protein yield (mg/L expression culture)..................................................... 46 
3.2 Steady-state enzyme parameters................................................................. 49 
3.3 Tm (⁰C)........................................................................................................ 53 
3.4 Theoretical pIs............................................................................................ 54 
3.5 IC50 (nM)..................................................................................................... 57 
 
LIST OF FIGURES 
Figure Page 
1.1 
World map comparing areas with endemic DENV and areas inhabited 
by the A. aegypti mosquito....................................................................... 
4 
1.2 Overview of the flavivirus intracellular life cycle.................................... 6 
1.3 E protein organization on the surface of a mature flavivirus……............ 8 
1.4 Schematic representation of the DENV genome and polyprotein............ 10 
1.5 
Schematic representation of NS2B-NS3pro construct from flaviviral 
polyprotein................................................................................................ 
17 
1.6 DENV NS3pro protein construct sequence alignment............................. 18 
1.7 
DENV NS2B47NS3pro structure in open conformation versus WNV 
structure in a closed conformation with an inhibitor bound..................... 
20 
1.8 Two structural conformations of the NS2B18NS3 full-length protein...... 23 
1.9 
Proposed NS2B47NS3 full-length protein interaction with lipid 
membrane model....................................................................................... 
25 
1.10 
SPR lipid binding sensogram for DENV 4 NS2B18NS3 and HT29-32 
mutant....................................................................................................... 
27 
3.1 Protein expression and purification profile............................................... 45 
3.2 Final protein products............................................................................... 46 
3.3 Enzyme saturation curves for D4WT and mutants................................... 48 
3.4 Thermal shift for D2WT and mutants....................................................... 52 
3.5 Native gel analysis.................................................................................... 55 
3.6 D1WT IC50 curve for aprotinin................................................................. 56 
3.7 Protein crystals for D2WT........................................................................ 59 
3.8 D2WT and mutants lipid binding SPR sensogram................................... 60 
3.9 D2WT lipid binding SPR sensogram followed by aprotinin binding....... 64 
4.1 
Interactions between hydrophobic turn and neighboring protein as in 
crystal formation....................................................................................... 
69 
4.2 
Interactions between hydrophobic turn of D2A30 and D2S30 proteins 
and neighboring protein as in a crystal formation.................................... 
70 
 
X 
 
ABBREVIATIONS 
ADE Antibody dependent enhancement 
APS Ammonium persulfate 
C Capsid protein 
DENV Dengue virus 
DF Dengue fever 
DHF Dengue hemorrhagic fever 
DLS Dynamic light scattering 
DSS Dengue shock syndrome 
E Envelope protein 
FPLC Fast protein liquid chromatography 
HT29-32 
Hydrophobic amino-acid turn in NS3pro located at residues 29 
to 32 
HTS High throughput screen 
IC50 Concentration giving half maximal inhibition 
IMAC Immobilized metal affinity chromatography 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
JEV Japanese encephalitis virus 
kcat 
“Turnover” number. The maximum number of enzymatic 
reactions catalyzed per unit time 
Km Michaelis-Menton constant 
LB Luria broth 
LBA Luria broth with ampicillin added 
LBAC Luria broth with ampicillin and chloramphicol added 
M Membrane protein 
mRNA Messenger RNA 
MTase S-adenosyl-methionine transferase 
NLS Nuclear localization sequence 
NS Non-structural protein 
NTPase Nucleoside triphosphatase 
NS3hel Flavivirus NS3 helicase domain 
NS3pro Flavivirus NS3 protein protease domain 
OG n-Octyl-β-D-glucopyranoside 
PCR Polymerase chain reaction 
pI Isoelectronic point 
P-Loop Phosphate loop 
POPC 1-Palmitoyl-2-Oleoyl-n-Glycero-3-Phosphocholine 
prM Membrane protein precursor 
RdRp RNA-dependent RNA polymerase 
XI 
 
RFU Relative fluorescence units 
RU Response units 
SDM Site-directed mutagenesis 
SDS-PAGE Sodium dodecyl sulfate - polyacrylamide gel electrophoresis 
SPR Surface Plasmon Resonance biosensing 
TBE Tick-borne encephalitis virus 
TEMED Tetramethylethylenediamine 
Tm Melting temperature 
Vmax Maximal velocity 
WHO World Health Organization 
WNV West Nile virus 
WT Wild-type 
YFV Yellow fever virus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  | 1 
 
 
1. INTRODUCTION 
 
1.1 Dengue Virus Classification 
 
Dengue virus (DENV) is a mosquito-borne human pathogen of global 
significance. A member of the family Flaviviridae, DENV was first described 
in the 18
th
 century and was isolated during World War II. The Flaviviridae 
family is divided into three genera: Flavivirus, Pestivirus, and Hepacivirus. 
Within the Flavivirus  genus are over seventy different viruses, over half of 
which are able to cause disease in humans. A few of the most well-known 
flaviviruses are DENV, YFV, West Nile encephalitis virus (WNV), tick-borne 
encephalitis virus (TBE), and Japanese encephalitis virus (JEV).  In recent 
decades, many of these viruses have shown a marked increase in global 
disease burden and have thus become especially important pathogens in the 
world today (Richman et al., 2002). 
 
1.2 Pathogenesis, Transmission, and Epidemiology of Dengue Virus 
 
1.2.1 Vector 
  
DENV is a vector-borne virus and is transmitted by the Aedes aegypti 
mosquito. DENV infection occurs when a mosquito carrying the virus bites a 
person to take a blood meal and passively injects DENV subcutaneously. New 
infections occur as the mosquito feeds multiple times and the virus is 
transferred between the people who were bitten. The A. aegypti mosquito 
often breeds in artificial containers, such as flowerpots or rain gutters, and 
bites in human inhabited environments, usually during the morning and late 
afternoon. In rural tropical and subtropical areas, the mosquito species Aedes 
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albopictus, rather than A. aegypti, is the primary vector for human-to-human 
transmission (Gratz, 2004). 
 
1.2.2 Pathogenesis 
 
There are four different DENV serotypes (DENV 1-4), all of which are 
able to infect and cause disease in humans. Upon infection, the virus targets a 
variety of cells, such as dendritic cells, endothelial cells, and macrophages 
(Jessie et al., 2004; Rodenhuis-Zybert et al., 2010). Primary infection with one 
DENV serotype induces a lifelong immunity against the specific type with 
which the person was infected. The four different serotypes, however, are 
sufficiently dissimilar in terms of antigenicity, so long term cross-protection 
between serotypes does not occur. Severe dengue mostly occurs upon 
secondary infection with a different serotype since neutralizing antibodies 
from the previous infection are unable to clear the new virus. In a process 
called antibody-dependent enhancement (ADE), macrophages engulf virus 
particles coated in non-neutralizing antibodies but are not able to inactivate the 
virus. As the infected macrophages travel through the body‟s lymphatic and 
circulatory systems, the infection is spread throughout the body (Halstead and 
O'Rourke, 1977). If infected macrophages are targeted for destruction by 
immune cells, however, infectious viral particles are released upon lysis. 
Vasopermeability factors and activators of complement are expelled into the 
extracellular space when the macrophages are destroyed (Halstead et al., 
1980). The release of virus and other molecules produces a complex immune 
response which can result in plasma leakage, shock, and hemorrhage within 
the body. The host‟s immune response to DENV and the ability to undergo 
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ADE are key contributing factors that determine the severity of DENV 
infection (Rodenhuis-Zybert et al., 2010). 
 
1.2.3 Physical Manifestations 
 
DENV infection produces a broad spectrum of illness in humans, from 
asymptomatic infection to severe disease. It is the etiological agent for dengue 
fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome 
(DSS). DF, an acute and self-limiting form of DENV infection, is the disease 
manifestation which afflicts most patients.  A small proportion, however, will 
develop the more severe disease complications associated with DHF and DSS 
(Gubler, 1998). According to the World Health Organization (WHO), DENV 
infection can be described in three phases: febrile, critical, and recovery 
(WHO, 2009b). During the febrile phase, which is self-limiting and usually 
lasts 2-7 days, patients often experience a sudden fever and headache 
accompanied by generalized muscle and joint pains (Rigau-Perez et al., 1998). 
If the febrile phase progresses to the critical phase, patients may experience 
life-threatening plasma leakage. If fluid replacement does not take place 
immediately, complications such as gastrointestinal bleeding may occur. The 
recovery phase follows patient survival of the critical phase and usually lasts 
24 hours. During this time, extra-vascular compartment fluid is re-absorbed as 
the patient‟s general well-being improves and symptoms abate 
(Srikiatkhachorn, 2009). A variety of factors related to the host, virus and 
environment play a role in determining the severity of DENV infection. 
Examples include a host‟s previous exposure to the virus, the host‟s immune 
system and ability to clear the virus, the level of circulating virus within the 
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host, genetic factors of both the host and virus, viral serotype, and the presence 
and prevalence of the mosquito vector in the environment where the host 
resides (Gubler et al., 1981a; Gubler et al., 1981b; Halstead, 2003; Pant et al., 
1973; Rico-Hesse, 1990; Vaughn et al., 2000).  
 
1.2.4 Epidemiology and Global Significance 
 
The global incidence of DENV has rapidly increased in recent decades 
(WHO, 2009a). The WHO estimates that over 50 million people are infected 
with DENV each year, while 2.5 billion people are at risk (WHO, 2009b). 
DENV transmission occurs in tropical and subtropical areas around the world 
and is only limited by the geographical boundaries of its vector, the A. aegypti 
mosquito (Fig 1.1). In recent decades, climate change and increased 
international air travel have become contributing factors to a rise in the 
number of DENV infections (WHO, 2009b; Wilder-Smith and Deen, 2008).  
 
Figure 1.1: World map indicating countries at risk for dengue transmission 
Global distribution of DENV in 2006. (Copyright 2006 World Health 
Organization.) 
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As the world‟s most-rapidly spreading mosquito-borne viral disease, 
DENV has shown a thirty-fold increase in disease burden in the past 50 years 
(WHO, 2009b). Today, over 100 countries experience endemic DENV, 
whereas only 9 countries were endemic in 1950 (WHO, 2009a). Such 
staggering statistics illustrate an immediate need for increased DENV control 
and through improved prevention and treatment options.  
 
1.3 Dengue Virus Life Cycle and Replication Overview 
 
The DENV life cycle can be described in four steps: cell entry and 
viral uncoating, polyprotein translation and processing, RNA replication, and 
cell exit. Figure 1.2 shows a diagram of main steps that take place in the 
intracellular virus life cycle. 
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Figure 1.2: Overview of the flavivirus intracellular lifecycle  
Viral entry occurs either via cellular receptors or via antibody Fc receptors. 
Once endocytosed, the virus undergoes membrane fusion with the host cell 
endosome and the viral nucleocapsid is released into the cytosol. The (+)-
ssRNA genome is used for both translation of a polyprotein and genome 
replication. Fully assembled virus particles exit the cell via a secretory 
pathway from the ER. (Reprinted from “Towards the design of antiviral 
inhibitors against flaviviruses: The case for the multifunctional NS3 protein 
from dengue virus as a target,” by Lescar, J, Luo, D, Xu, T, Sampath, A, Lim, 
S, Canard, B, and Vasudevan, S, 2008, Antiviral Research, 80, 95-101. 
Copyright 2008 by Elsevier. Reprinted with permission.) 
 
 
A viral particle gains entry to a cell in one of two ways: either the virus 
is directly endocytosed through a clathrin-mediated pathway or the virus is 
recognized by antibody and the entire antibody-virus complex is endocytosed 
(Fig.1.2) (Peng et al., 2009; Stiasny et al., 2009). Inside the newly formed 
endosome, the viral surface proteins undergo major structural changes and 
fuse the lipid membrane from the virus envelope with the cell‟s endosomal 
membrane (Bressanelli et al., 2004; Modis et al., 2004). The viral RNA 
genome is released into the cellular cytoplasm and serves as a messenger RNA 
(mRNA) which can be directly translated into protein by the host cell 
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machinery (Clyde et al., 2006; Rodenhuis-Zybert et al., 2010). The translation 
occurs in convoluted membranes derived from the endoplasmic reticulum 
(ER) (Lindenbach and Rice, 2003). The genome is translated as a single 
polyprotein and is looped throughout the ER membranes. The polyprotein is 
processed by both host and viral proteases into 3 structural and 7 non-
structural proteins. Once translated, several of the NS proteins and some host 
cellular factors combine to form a replication complex which is stable and 
membrane bound. After protein translation and folding, the NS proteins 
initiate replication of the viral genome (Rodenhuis-Zybert et al., 2010). The 
positive-sense viral RNA genome is first transcribed into  a complementary 
negative-sense RNA, which is then translated back into multiple copies of the 
positive sense RNA genome for packaging into a new virion (Knipe and 
Howley, 2007). Once proteins have been translated and new viral genomes 
have been synthesized, new virions are packaged within the cell. Similar to 
other flaviviruses, DENV likely assembles all necessary proteins and a copy of 
the viral genome via a special packaging pathway. The assembly buds directly 
into the ER, gaining a lipid bilayer envelope in the process. The virions then 
transit the secretory pathway and are released from the cell surface (Knipe and 
Howley, 2007).  
 
1.4 Dengue Virus Structure 
 
1.4.1 Structure and Physical Properties of the Viral Particle 
 
The DENV virion is approximately 50nm in diameter and consists of 
an icosahedral nucleocapsid surrounded by a lipid bilayer envelope. The 
nucleocapsid consists of capsid (C) proteins, is 25-30 nm in diameter, and 
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surrounds the viral genome. All flavivurses, including DENV, have a positive-
sense, single-stranded RNA genome containing approximately 11,000 
nucleotides. The envelope is studded with two viral proteins, envelope (E) and 
membrane (M) (Hase et al., 1987). On the surface of the virion, the E protein 
forms dimers which pack into 30 organized “rafts” (Fig. 1.3) (Zhang et al., 
2004). The M protein is produced during viral maturation and consists of a 
fragment of the precursor M (prM) protein. The prM protein stabilizes the E 
protein and is cleaved upon virus exit from the cell, resulting in exposed M 
and E proteins on the surface of a mature virion.  
 
 
Figure 1.3: E protein organization on the surface of a mature flavivirus 
A) E protein orientation on the surface of the virus. One of the E protein dimer 
is highlighted and enlarged to show detail. (Reprinted from “Prospects for a 
dengue virus vaccine,” by Whitehead, SS, Blaney, JE, Durbin, AP, and 
Murphy, BR, 2007, Nature Reviews Microbiology, 5, 518-528. Copyright 
2007 by Macmillan Publishers Ltd. Reprinted with permission.) 
 
1.4.2 Genome 
The DENV genome is 10.7kb in length and contains a single, positive 
sense RNA genome. The viral RNA genome consists of a conserved type I 
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methyl-guanosine 5‟ cap structure, a short 5‟ non-coding region, a single open 
reading frame (ORF), and a 3‟ non-coding terminus which lacks a poly(A) tail. 
It is translated as a single polyprotein and is subsequently cleaved by host and 
viral proteases. Each flaviviral genome encodes 10 different proteins: 3 
structural proteins followed downstream by 7 non-structural (NS) proteins 
(Richman et al., 2002). The order of proteins from the 5‟ end is C, prM, E, 
NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5. Non-coding regions flank the 
open reading frame at both the 5‟ and 3‟ ends (Knipe and Howley, 2007). 
While cellular proteases cleave within the lumen of the ER, the viral protease 
cleaves the polyprotein on the cytoplasmic side of the membrane (Fig. 1.4). 
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Figure 1.4: Schematic representation of the DENV genome and polyprotein 
A) Overall organization of the DENV genome. The genome features a 5‟ UTR 
and CAP structure, structural proteins at the 5‟ end, followed by non-structural 
proteins. The genome has a 3‟ UTR, but lacks a poly(A)tail. B) DENV 
polyprotein as organized within the ER membrane. Enzymatic cleavage sites 
of the host and viral NS2B-NS3 protease compex are indicated by small 
arrows along the polyprotein. (Reprinted from “Structural proteomics of 
dengue virus,” by Perera, R, and Kuhn, RJ, 2008, Current Opinion in 
Microbiology, 11, 369-77. Copyright 2008 by Elsevier. Reprinted with 
permission.) 
 
 
1.4.3 Proteins 
 
1.4.3.1 Structural Proteins 
The DENV genome encodes 3 structural proteins: C, prM, and E. The 
first protein to be translated is the capsid (C) protein (Fig. 1.4). Multiple 
copies of the C protein encapsulate the virus genome and form the 
nucleocapsid core.  The protein is approximately 11kD in size and has a highly 
basic character. It is found in both the cytoplasm and nucleus of infected cells 
(Knipe and Howley, 2007; Samsa et al., 2009). The 8kD membrane (M) 
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protein is proteolytically processed from its 22kD glycoslated precursor 
protein prM. The prM protein cleavage event precedes viral exit from the cell. 
As mentioned previously, the prM protein stabilizes the E protein until the 
virus exits the cell. The event is crucial in the viral lifecycle as interruption of 
this cleavage event greatly affects viral infectivity. Finally, the E protein is the 
main antigenic determinant of the virus. It has three distinct domains, I, II, and 
III, where domain I is positioned between domain II, the homodimerization 
domain, and the immunoglobulin-like domain III (Fig. 1.3) (Rodenhuis-Zybert 
et al., 2010). It is involved in both the attachment and fusion of the virus 
particle to the host cell. Mutations in the E protein significantly affect 
virulence, and antibodies specific for the E protein are responsible ADE 
(Richman et al., 2002). 
 
1.4.3.2 Nonstructural Proteins 
 
NS1 
 
The 7 non-structural proteins are encoded 3‟ to the structural proteins 
and have been mapped by limited amino- and carboxy-terminal amino acid 
sequencing. NS1, the first nonstructural protein following the E protein in the 
flavivirus genome, is approximately 48kD in size and is synthesized as a 
hydrophilic, water soluble, monomeric glycoprotein in the endoplasmic 
reticulum. Shortly after synthesis, the protein forms non-covalently bound 
homodimers, which are more hydrophobic in character. The NS1 protein 
contains two Asn-X-Ser/Thr sites for the addition of N-linked carbohydrates 
(Henchal and Putnak, 1990). Recent research conducted on the flavivirus NS1 
proteins, in particular DENV, has focused on the utility of NS1 as a clinical 
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diagnostic tool. NS1 correlates with levels of viremia and is a possible 
predictor of the severity of symptoms which can develop after DENV 
infection (Libraty et al., 2002b). 
NS2 
The NS2 portion of the DENV genome encodes two proteins, NS2A 
and NS2B, which are 20kD and 14.5kD in size, respectively. Both proteins 
contain transmembrane domains and are involved in the proteolytic processing 
of the viral polyprotein. NS2A, along with 8 amino acids from NS1, is 
required for processing the NS1/NS2A junction, while NS2B associates with 
NS3 for processing of several viral proteins (Falgout et al., 1989; Falgout et 
al., 1991). The NS2B protein contains three hydrophobic regions flanking a 
conserved, forty-seven amino acid long hydrophilic domain. The hydrophobic 
regions, amino acid residues N-terminal to 49 and C-terminal to 96 within 
NS2B, are presumed to be anchored within a host cell membrane. The 
hydrophilic domain from amino acid residues 49 to 95 (NS2B47) in the central 
core of NS2B acts as the cofactor of NS3 protease and is critical for its 
efficient activation (Clum et al., 1997; Falgout et al., 1993; Leung et al., 2001; 
Niyomrattanakit et al., 2004).  
NS3 
 
The DENV NS3 protein is 70kD in size and 618 amino acids long. It is 
the second largest protein in the DENV proteome. A trifunctional protein, NS3 
consists of a trypsin-like serine protease (NS3pro) at the N-terminus linked 
through eleven amino acids to an ATP-driven helicase and RNA 
triphosphatase (NTPase) domain (NS3hel) at the C-terminus. Mutagenesis 
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studies have shown that impairing either the proteolytic or the 
helicase/NTPase activities of NS3 leads to the production of defective virus 
which is unable to infect cells. The enzymatic activities of NS3 are thus 
essential for viral replication (Matusan et al., 2001). 
The NS3pro domain is located within the N-terminal 168 amino acids 
of the full-length NS3 protein (Lescar et al., 2008). Several structural motifs, 
as well as the characteristic catalytic triad (His-51,Asp-75,Ser-135), are 
conserved among the four DENV serotypes and among other flaviviruses 
(Chambers et al., 1990b). Polyprotein processing by the heterodimeric NS2B-
NS3 complex is critical for the viral replication cycle (Chambers et al., 1990a; 
Chambers et al., 1990b; Falgout et al., 1991). Responsible for the majority of 
polyprotein processing, the NS2B-NS3 complex catalyzes cis cleavage at the 
junctions of NS2A/NS2B and NS2B/NS3, trans cleavage between NS3/NS4A 
and NS4B/NS5 and at internal sites within the C protein, NS2A, NS3, and 
NS4A (Bera et al., 2007; Clum et al., 1997; Preugschat and Strauss, 1991; 
Preugschat et al., 1990). Host proteases, signalase and furin mediate cleavage 
at the remaining sites (Falgout and Markoff, 1995; Preugschat et al., 1990; 
Speight et al., 1988).  
The NS3hel/NTPase domain is located between amino acids 180 and 
618 in the NS3 protein. Several structural motifs in this C-terminal domain 
classify it as a member of the superfamily 2 of RNA helicases/NTPases. The 
helicase domain is implicated to play a role in unwinding the dsRNA 
intermediate formed during viral genome replication. Impaired helicase 
activity prevents DENV from replicating (Xu et al., 2005). The orientation of 
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the DENV NS3hel/NTPase domain with regard to NS3pro likely plays a role 
in regulating viral replication (Luo et al., 2010).  
 
NS4 
 
Like the two proteins encoded in the NS2 region of the DENV 
genome, the NS4 region encodes two proteins, NS4A and NS4B. Both 
proteins are hydrophobic and are 8kD and 27kD in size respectively. The NS4 
proteins are less well-characterized than other DENV NS proteins, but their 
small, hydrophobic nature implies their involvement in the proper localization 
of viral proteins and RNA during synthesis and virus assembly (Clyde and 
Harris, 2006; Clyde et al., 2006; Knipe and Howley, 2007). The C-terminal 
region of NS4A serves as translocation signal for NS4B into the lumen of the 
ER. NS4A interacts with the membrane in four hydrophobic regions which 
also mediate targeting of the protein (Miller et al., 2007). The NS4B protein 
has been shown to interact with NS3 and dissociate it from single-stranded 
RNA (Umareddy et al., 2006). It is an intergral membrane protein, containing 
four central transmembrane domains (Knipe and Howley, 2007). Recently, 
both NS4 proteins have been shown to inhibit interferon (IFN) production 
(Munoz-Jordan et al., 2003). 
 
NS5 
  
The NS5 protein is both the largest, at 104kD, and most conserved 
DENV protein. It shares a minimum 70% sequence identity across the four 
DENV serotypes. The N-terminal 260-270 amino acids of the DENV NS5 
proteins contains a 33kD S-adenosyl-methionine transferase domain (MTase) 
(Koonin and Ilyina, 1993). Following the C-terminus of the DENV NS5 
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protein MTase domain is a short linker region, followed by a RNA-dependent 
RNA polymerase (RdRp) (Koonin, 1991; Poch et al., 1989), which is able to 
initiate RNA synthesis de novo (Ackermann and Padmanabhan, 2001; 
Nomaguchi et al., 2003).  As is typical of RdRps, the DENV RdRp consists of 
three subdomains: fingers, palm, and thumb. The DENV NS5 RdRp crystal 
structures have shown a protein in the „closed‟ conformation, where the 
fingers and thumb are connected. This is especially characteristic of RdRps 
which are capable of de novo synthesis. The NS5 protein also has two nuclear 
localization sequences (NLS), which are located at the surface of the fingers 
sub-domain. These sequences allow transportation of  NS5 protein into the 
nucleus of a virus-infected host cell (Bollati et al., 2010). When in the 
cytoplasm, the NS5 protein has been shown to associate with NS3 protein 
(Kapoor et al., 1995). A replication complex is formed by the association of 
these two proteins, wherein viral genome replication can occur. The NS3 and 
NS5 proteins contain all of the known enzymatic activities of DENV proteins. 
 
1.5 Structure and Function of Dengue Virus NS3 
 
The flaviviral NS3 protein provides three separate enzymatic activities 
for the virus. It functions as a protease, helicase, and NTPase. Structures for 
the NS3pro and NS3hel/NTPase domains, as well as the DENV full-length 
NS3 protein have been elucidated (Erbel et al., 2006; Luo et al., 2008; Xu et 
al., 2005). Both the NS3pro and the full-length protein have a tendency to 
form aggregates and are insoluble when expressed in bacteria without NS2B. 
A minimum of 18 amino acids, residues 49-66, from the central hydrophilic 
region of NS2B is required to retain NS3 structure and to ensure solubility, 
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while a minimum of 47 amino acids, residues 49-95, are needed to maintain 
protease activity.  
1.5.1 NS3 Protease 
 
The NS3 protease is the focus of this study. Structural and functional 
studies of NS3pro are usually carried out with NS2B47 tethered to NS3pro via 
a nonapeptide flexible linker (G4SG4). (Bera et al., 2007). Several peptides 
were tested to link NS2B to NS3. The G4SG4 fusion peptide was found to be 
an optimal linker for DENV 2 NS2B-NS3 as it is flexible and unlikely to 
undergo enzymatic cleavage, thus preventing enzymatic separation of NS2B47 
from NS3(Leung et al., 2001). Several groups have used this G4SG4 linker 
peptide for a variety of biochemical and mutagenesis studies on protease 
specificity (Li et al., 2005; Nall, 2004). 
The protein constructs used in this study consist of an N-terminal His-
Tag bound to NS2B47. This is tethered through the linker G4SG4 to the N-
terminal 185 amino acids of NS3, which encompasses the NS3 protease 
domain (Fig. 1.5, Fig. 1.6).  
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Figure 1.5: Schematic representation of NS2B47NS3pro construct from 
flaviviral polyprotein 
Schematic representation of a flaviviral polyprotein which highlights the 
regions used for protein constructs in this study. A) Diagram of the flaviviral 
polyprotein highlighting regions of NS2B and NS3 used for protein constructs 
in this study. The HT29-32 turn is highlighted in red. B) Diagram of protein 
constructs used in this study. 
 
The catalytic mechanism for serine proteases, such as DENV NS3, has 
been well characterized and involves a two-step process of acylation and 
deacylation. The DENV catalytic triad of His-51, Asp-75, Ser-135 plays an 
important role in the cleavage event. Similar in terms of activity and function, 
NS3pro from all four DENV serotypes share a high degree of sequence 
homology (Fig. 1.6, Table 1). The consensus DENV NS3pro substrate 
cleavage motif consists of a pair of basic amino acids: Lys-Arg or Arg-Arg. 
The locations of these residues are identified as positions P2 and P1 before the 
site of cleavage.  The site is followed immediately in position P1‟ by a short 
chain amino acid, such as Gly, Ala, or Ser (Chambers et al., 1991; 
Niyomrattanakit et al., 2006; Preugschat et al., 1991). 
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Figure 1.6: DENV NS3pro protein construct sequence alignment  
Alignment of the NS3pro constructs used for structural studies of all four 
DENV serotypes. The construct has an N-terminal His-Tag which is utilized 
for protein purification. NS2B47 follows and is connected to the NS3pro via 
the flexible G4SG4 linker. A hydrophobic turn at amino acids 29-32 is labeled 
as HT29-32, and the catalytic triad within NS3pro is labeled with asterisks.  
 
 
Table 1 
NS3 protease percent identity matrix 
 DENV 1  DENV 2  DENV 3  
DENV 1  - - - 
DENV 2  69 - - 
DENV 3  73 68 - 
DENV 4  63 66 66 
Amino acid sequences of DENV NS3pro for all four DENV serotypes were 
used. Sequences were aligned and analyzed using the ClustalW2 method 
(www.ebi.ac.uk/clustalw/).  
 
Atomic structures of the DENV 2 NS2B47NS3pro have been solved 
and compared to other flavivirus NS3pro structures (Aleshin et al., 2007; 
Erbel et al., 2006; Robin et al., 2009). Subsequently, NS3pro was also solved 
as a domain within the DENV 4 NS2B18NS3 full-length protein (Luo et al., 
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2010; Luo et al., 2008). Flavivirus NS3 proteases consists of two, six-stranded 
β-barrel domains which form a characteristic chymotrypsin-like fold. The 
catalytic triad (His-51, Asp-75, Ser-135) is located at the cleft between the 
barrels. Figure 1.7 compares the structure of NSB47NS3pro of DENV 2 to that 
of WNV. The two proteases have 50% sequence identity and share a high 
degree of structural similarity. The DENV NS3pro was solved to a resolution 
of 1.5 Å, while the WNV structure was solved at 1.68 Å. As shown in Figure 
1.7, the WNV structure was solved in the closed conformation and in the 
presence of an inhibitor, benzoyl-norleucine-lysine-arginine-arginine-aldehyde 
(Bz-nKRR-H). A closed conformation occurs when an inhibitor or ligand is 
bound to the protease and represents a structure with a C-terminal portion of 
the NS2B47 cofactor lining the substrate binding site. In the WNV structure, 
Asp-82 to Phe-85 of the NS2B47 interacts with the inhibitor in the active site in 
the NS3pro. The C-terminal portion of the cofactor wraps around the protease 
like a belt. The structure of DENV NS3pro, however, has only been solved in 
an open conformation, where the NS2B cofactor is located far from the 
substrate binding site. 
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Figure 1.7: DENV NS2B47NS3pro structure in open conformation versus WNV 
structure in a closed conformation with an inhibitor bound 
Protein structures of A) DENV and B) WNV NS3pro (gray) bound to DENV 
and WNV NS2B47 (yellow), respectively. The DENV NS3pro is in an open 
conformation, while the WNV NS3pro is in the presence of the inhibitor Bz-
nKRR-H and is in the closed conformation. No electron density was observed 
for NS2B amino acid residues 77-84 in the DENV structure. Beta sheets and 
helices are labeled for orientation. (Reprinted from “Structural basis for the 
activation of flaviviral NS3 proteases from dengue and West Nile virus,” by 
Erbel, P, Schiering, N, D'Arcy, A, Renatus, M, Kroemer, M, Lim, SP, Yin, Z, 
Keller, TH, Vasudevan, SG, and Hommel, U, 2006, Nature Structural & 
Molecular Biology, 13, 372-373. Copyright 2006 by Macmillan Publishers 
Ltd. Reprinted with permission.) 
 
1.5.2 NS3 Helicase and NTPase 
 
The C-terminal region of the NS3 protein contains a helicase and 
NTPase domain. The NS3 helicase is involved in unwinding the the dsRNA 
intermediate which is formed during viral genome replication. The structure of 
NS3hel, residues 171-618 in DENV NS3, shows a flattened structure with 
three subdomains (I, II, and III) of approximately 140 amino acids each.  The 
protein has a long tunnel which crosses the center of the protein. Like most 
other helicases, the protein is driven by ATP, the binding site for which is 
located between subdomains I and II.  (Xu et al., 2005). The mechanism by 
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which the chemical energy obtained from the hydrolysis of ATP is channeled 
to accomplish the RNA strand separation is unknown.  
Studies suggest that the activity of the NS3hel domain is influenced by 
the presence of the NS3pro (Xu et al., 2005), since differences in substrate 
specificity and ATPase activity exist between NS3hel alone and NS3 full-
length protein (Chernov et al., 2008; Luo et al., 2008). When NS3 full-length 
protein is compared to NS3 without the protease domain (amino acids 171 to 
618), the NS3 full-length protein showed a 30-fold increase in dsRNA 
unwinding activity. It is suggested that a dynamic interaction between the 
NS3pro and NS3hel domains occurs which influences nucleotide binding (Luo 
et al., 2008). 
 
1.5.3 NS3 Full-Length Protein 
 
Recently, two crystal structures of the full-length NS3 protein from 
DENV 4 covalently attached to 18 residues of the NS2B cofactor 
(NS2B18NS3) have been solved. The 18 residues are simply required to 
maintain the structure of NS3pro. A full-length NS3 structure has not been 
solved with NS2B47, because the active protease degrades the protein. The 
first structure (Conformation I) was solved to a resolution of 3.15 Å and shows 
an elongated shape, with the protease domain located below the ATP binding 
site. An alternative structure (Conformation II), however, with the protease 
domain rotated approximately 161⁰ with respect to the helicase domain, was 
subsequently discovered using slightly different crystallization conditions 
(Fig. 1.8).  
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While in Conformation I, nucleotides were not able to bind to the 
structure, possibly due to steric clashes between the helicase nucleotide 
binding site and the protease domain. In Conformation II, however, ADP-
Mn
2+
 could be soaked into the structure, and the complex of NS3 protein with 
ADP-Mn
2+
 was solved. The primary structural difference between the two 
protein conformations is in the positioning of a phosphate loop (P-loop) and in 
residues Arg-460 to Gln-471 of the helicase domain. The P-loop interacts with 
the protease domain through hydrogen bonds in Conformation I but not in 
Conformation II. According to the structural studies, the helicase in 
Conformation II is in a closed conformation, which is able to capture the 
binding of ADP-MN
2+
 (Luo et al., 2010).  
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Figure 1.8: Two structural conformations of the NS2B18NS3 full-length protein 
Side-by-side view of the two structural conformations of the full-length 
NS2B18NS3. The α-helix and β-strand secondary structures of NS3 protein are 
shown in cyan and magenta respectively, while the NS2B47 is colored red. The 
region linking the protease and helicase domains is shown is green. N-terminal 
residues are labeled. The orientation of ADP-Mn
2+
 within the NS3 protein 
structure is included in Conformation II. (This research was originally 
published in the Journal of Biological Chemistry. Luo, D, Wei, N, Doan, DN, 
Paradkar, PN, Chong, Y, Davidson, AD, Kotaka, M, Lescar, J, and 
Vasudevan, SG. Flexibility between the protease and helicase domains of the 
dengue virus NS3 protein conferred by the linker region and its functional 
implications. Journal of Biological Chemistry. 2010; 285:18817-18827. © the 
American Society for Biochemistry and Molecular Biology.) 
 
A remarkable feature of the NS3 protein is its inherent ability to 
undergo autocleavage at three sites within the NS2B-NS3 protein complex. 
For these cleavage events to occur, the NS3 protein has to accommodate its 
own polypeptide substrate into its protease active site. For such intramolecular 
proteolysis events to occur, NS3pro must exhibit immense flexibility and 
plasticity. 
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Structures with the protease in a closed conformation with either small 
compounds or peptides bound within the active site are desired as such 
visualization may lead to insight into important amino acid residues in the 
protease domain, a better understanding of the full-length protein and thus to 
the development of anti-viral compounds which can be used for treating 
DENV.  
 
1.6 Membrane Association Model for NS3 
 
A model which describes the orientation of the full-length NS3 protein 
with regard to a lipid membrane surface was proposed by Luo and coworkers. 
The model was created by superimposing the protease domain from the 
NS2B18NS3 full-length crystal structures in Conformations I and II onto a 
membrane-bound NS2B-NS3pro structure. The membrane-bound NS3pro 
domain was generated by comparisons of the DENV NS2B47NS3pro structure 
in an open conformation and the WNV  NS2B47NS3pro in the closed 
conformation with substrate bound. NS2B anchors the protein complex to the 
lipid membrane via two transmembrane loops (Luo et al., 2010). Between 
these loops is the hydrophilic NS2B domain which attaches to NS3pro. 
(Chambers et al., 1991; Lescar et al., 2008; Lindenbach and Rice, 2003).  
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Figure 1.9: Proposed NS2B-NS3 full-length protein interaction with lipid 
membrane model 
Current model of the DENV 2 full-length NS3 protein bound to NS2B47. The 
model is based on recent crystallographic structure determination the full 
length NS2B18NS3 protein, the structure of NS2B47NS3pro and on homology 
with the structure of WNV NS2B47NS3pro with substrate bound. A) Proposed 
association with the membrane in Conformation I B) Proposed association 
with the membrane in Conformation II. (This research was originally 
published in the Journal of Biological Chemistry. Luo, D, Wei, N, Doan, DN, 
Paradkar, PN, Chong, Y, Davidson, AD, Kotaka, M, Lescar, J, and 
Vasudevan, SG. Flexibility between the protease and helicase domains of the 
dengue virus NS3 protein conferred by the linker region and its functional 
implications. Journal of Biological Chemistry. 2010; 285:18817-18827. © the 
American Society for Biochemistry and Molecular Biology.) 
 
In their model, the group noticed a conserved, exposed hydrophobic 
turn located within the NS3pro which, they believed, may also interact with 
the membrane. In Figure 1.9, this turn is labeled GLFG. Conserved across 
flaviviruses, it consists of a Gly amino acid residue at position 29 in NS3pro, 
followed by two hydrophobic amino acids (a combination of Leu, Ile, or Phe 
depending on the DENV serotype) at positions 30 and 31, and ending in the 
fourth position, residue 32, with a second Gly.  This hydrophobic turn in 
NS3pro amino acid residues 29-32 will be referred to as HT29-32 in this text. 
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Together, the two transmembrane domains of the NS2B and the HT29-32 in 
NS3pro form a tripod-like structure on the surface of the lipid membrane. 
With regards to RNA binding by the helicase, in Conformation I, which is 
indicated in Figure 1.9 A, the RNA binding groove is facing the membrane 
and RNA is not able to enter the active site. However, in Conformation II, 
which is indicated in Figure 1.9 B, the RNA binding groove is exposed and 
able to dock both RNA for cleavage and ATP for hydrolysis. Since several 
studies have shown that viral RNA replication takes place at many places 
within the cell, each conformation may be present in different cellular 
locations (Luo et al., 2010). The varied degrees of orientation between the 
NS3hel and NS3pro are predicted to regulate viral replication (Assenberg et 
al., 2009). 
To verify the interaction between the HT29-32 in DENV 4 NS3pro and 
a planar liposome membrane, Surface Plasmon Resonance (SPR) biosensing 
was utilized by Luo et al. (Luo et al., 2010). They tested the affinities of 
DENV 4 NS2B18NS3 full-length protein (wt NS3) versus a mutant (L30F31-
S30S31) with two Ser amino acid residues replacing the two hydrophobic 
amino acids Leu and Phe in the protein loop. The protein Tyr 176 Ala (Y176) 
is used as a positive control for the experiment, because the mutation occurs in 
the linker region between NS3pro and NS3hel and is located away from the 
proposed site of membrane association. Y176A has the same hydrophobic 
loop residues (L30-F31) as the wild-type (WT) protein. As shown in Figure 
1.10, the L30F31-S30S31 mutant does not bind to the lipid surface, whereas 
both the wt NS3 and positive control show equally strong binding.  These 
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results confirm that the HT29-32 contributes to membrane association and 
verifies the orientation of the DENV protease to a lipid surface. 
 
 
Figure 1.10: SPR lipid binding sensogram for DENV 4 NS2B18NS3 and HT29-
32 mutant 
SPR sensogram comparing lipid association of the NS3pro HT29-32 mutant 
(L30F31-S30S31) in comparison to the wt NS3 protein. L30F31-S30S31 does 
not bind to the surface. Full-length DENV 4 NS2B18NS3 protein was used for 
the study. Y176A is a positive control. It contains a single Tyr to Ala mutation 
in the linker region between NS3pro and NS3hel, but it retains the same 
hydrophobic loop at NS3pro residues 29-32 as the wt NS3. (This research was 
originally published by the Journal of Biological Chemistry. Luo, D, Wei, N, 
Doan, DN, Paradkar, PN, Chong, Y, Davidson, AD, Kotaka, M, Lescar, J, and 
Vasudevan, SG. Flexibility between the protease and helicase domains of the 
dengue virus NS3 protein conferred by the linker region and its functional 
implications. Journal of Biological Chemistry. 2010; 285:18817-18827. © the 
American Society for Biochemistry and Molecular Biology.)  
 
By showing that the protease domain interacts with the lipid surface, 
Luo and coworkers (2010) were able to establish the orientation of the protein 
with regard to a lipid surface and develop their model. Defining the precise 
structural states that the NS3 protein exhibits will inevitably be valuable for 
designing inhibitors which can target these structures, or that inhibit the 
structural transitions between them. 
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1.7 The Role of HT29-32 in Dengue Virus NS3 Protease 
 
At present, no vaccines or therapies exist for the prevention of DENV. 
Current treatment for the disease focuses on the symptoms, rather than on 
preventing or eliminating the virus. Because of ADE, protection against one or 
more serotypes, even via vaccination, may lead to more serious disease, rather 
than immunity upon subsequent infection with a different DENV serotype.  
As an alternative to this dilemma, scientists are taking biochemical and 
therapeutic-based approaches to build a better understanding of how DENV 
virus functions within the cell and to design drugs which target specific viral 
mechanisms.  Viral proteins and their interactions have become important 
areas of study as inhibition of key viral mechanisms can lead to inhibition of 
the virus.  Compared to other related flaviviruses, DENV produces an acute, 
self-limiting disease. However, higher levels of circulating DENV virus 
correlate to increased disease severity (Gubler et al., 1981b; Libraty et al., 
2002a). If DENV infection is diagnosed at an early stage, anti-viral 
compounds may be administered which would immediately reduce viremia 
and thus decrease the severity of the disease.   
Of the ten flaviviral proteins, NS3 and NS5 contain all the known 
enzymatic activities for viral polyprotein processing and genome replication. 
Sufficient conservation of both viral proteins between the four DENV 
serotypes suggests that design of compounds against either viral protein could 
provide protection across all serotypes. Thus, DENV NS3 and NS5 proteins 
are key targets for the design of viral inhibitors. 
Several techniques have been utilized in the past for the design of 
antiviral inhibitors. One of these techniques, protein crystallization, is very 
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useful for gaining insight into an enzyme‟s structure and designing specific 
inhibitors for the enzyme. Although two DENV NS2B47NS3pro structures 
(DENV2 and DENV4) have been solved, the protein was always captured in 
an open conformation (Erbel et al., 2006; Luo et al., 2008). Developing a 
structure of DENV NS3pro which can be solved easily and in the closed 
conformation would be highly valuable for insight into specific amino acid 
interactions and for designing inhibitors against the enzyme for the prevention 
of DENV.  
NS2B18NS3 with a mutated HT29-32 has shown enhanced formation 
of protein crystals. The NS2B18NS3 protein with a double Ser mutation for the 
two central, hydrophobic residues of HT29-32, which was generated by Luo 
and coworkers and used for membrane association studies, crystallized more 
readily than the NS2B18NS3 WT HT29-32 (unpublished data and personal 
communication, Dr. Danny Doan). In this study, the HT29-32 will be explored 
with regard to biophysical properties, crystallization and membrane 
association for NS2B47NS3pro of all four DENV serotypes. If the protein 
crystallizes more easily, it can be used to further engineer NS3pro which can 
be crystallized in a closed conformation with an inhibitor bound. 
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1.8 AIMS 
 
1) To test whether directed mutations in the four amino-acid hydrophobic turn 
at residues 29-32 (HT29-32) affect DENV NS3 protease function and 
biophysical properties 
 
 
2)  To determine whether these mutations will enhance the protein‟s ability to 
form crystals and whether the mutant proteins could potentially lead to a 
protein whose structure can be solved in the closed conformation and in the 
presence of inhibitors  
 
3) To confirm membrane association of NS2B47NS3pro as was seen with the 
NS2B18NS3 full-length protein 
 
4) To conduct an initial assessment for utilizing Surface Plasmon Resonance 
(SPR) biosensing as a high throughput screening method for measuring the 
binding affinity of an inhibitor to the DENV NS3pro while the NS3pro is 
bound to a liposome surface 
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2. MATERIALS AND METHODS 
 
2.1 Plasmid Propagation 
 
pET15b plasmids  (Novagen) with serotype specific sequences of 
NS2B47NS3pro connected through the G4SG4 linker (Fig. 1.5, Fig. 1.6) were 
prepared as described in (Li et al., 2005) and were obtained through a kind gift 
from Dr. Siew Pheng Lim (Novartis Institute for Tropical Diseases, 
Singapore).  The protein constructs were cloned from the following virus 
strains: DENV 1 Hawaii, DENV 2 TSV01, DENV 3 S221/03, and DENV 4 
H241.  
The recombinant plasmids encoding NS2B47NS3pro were transformed 
into DH5α Escherichia coli cells and were grown on LBA agar plates 
overnight to obtain single bacterial colonies. A list of the broths and solid 
bacteria growth media is included in Table 2.2 at the end of this section. 
Single bacterial colonies were selected from the LBA agar plates with sterile 
pipette tips and transferred into 5ml LBA. One colony each was chosen for 
DENV 1-4. The inoculums were incubated at 37 ⁰C overnight while shaking at 
200rpm. The bacterial cells were collected by centrifugation at 6,000rpm for 
10 minutes in 1.5ml Eppendorf tubes. The plasmids were purified from the 
DH5α cells using a QIAprep Spin Mini-prep Kit (Qiagen, USA) following the 
protocol provided. The plasmid DNA was eluted with 50μL elution buffer 
(10mM Tris-HCl, pH 8.5) and DNA concentration was measured using a 
NanoDrop 2000 spectrophotometer (Thermo Scientific).  
Forward and reverse oligonucleotide primers were designed to both 
introduce double amino acid mutations into the NS2B47NS3pro sequence and 
to amplify plasmid DNA (Table 2.1). Mutations were introduced at amino acid 
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positions 30 and 31 from the N-terminus of NS3pro. The primers are 30 to 34 
nucleotides in length and were designed to change two hydrophobic amino 
acids, Leu-Leu (DENV 1), Ile-Leu (DENV 2), Ile-Phe (DENV 3), Leu-Phe 
(DENV 4), into Ala-Ala or Ser-Ser (Table 2.1). The most conservative 
changes in nucleotide sequence were chosen.  
Table 2.1 
Primers for mutagenesis 
Construct 
Name 
Amino Acid 
Mutation 
Primer 
Direction 
Sequence 
(mutations are underlined) 
 
D1A30 
 
LL → AA 
Forward 5‟ CTG CAA AGA GGA GCG  GCG GGC AGG TCC 
CAG 3‟ 
Reverse 5‟ CTG GGA CCT GCC CGC CGC TCC TCT TTG CAG 
3‟ 
 
D1S30 
 
LL → SS 
Forward 5‟ CTG CAA AGA GGA TCG TCG  GGC AGG TCC 
CAG 3‟ 
Reverse 5‟ CTG GGA CCT GCC CGA CGA TCC TCT TTG CAG 
3‟ 
 
D2A30 
 
IL → AA 
Forward 5‟ C  AAG CAG AAA GGG GCT GCA GGA TAC TCG 
CAG 3‟ 
Reverse 5‟ CTG CGA GTA TCC TGC AGC CCC TTT CTG CTT G 
3‟ 
 
D2S30 
 
IL → SS 
Forward 5‟ C AAG CAG AAA GGG AGT TCA GGA TAC TCG 
CAG 3‟ 
Reverse 5‟ CTG CGA GTA TCC TGA ACT CCC TTT CTG CTT G 
3‟ 
 
D3A30 
 
IF → AA 
Forward 5‟ C AAA CAG CAA GGA GCT GCT  GGG AAA ACC 
CAA G 3‟ 
Reverse 5‟ C TTG GGT TTT CCC AGC AGC TCC TTG CTG TTT 
G 3‟ 
 
D3S30 
 
IF → SS 
Forward 5‟ C AAA CAG CAA GGA AGT TCT  GGG AAA ACC 
CAA G 3‟ 
Reverse 5‟ C TTG GGT TTT CCC AGA ACT TCC TTG CTG TTT 
G 3‟ 
 
D4A30 
 
LF → AA 
Forward 5‟ C ATG CAA AGA GGG GCG GCT  GGG AAA ACT 
CAG G 3‟ 
Reverse 5‟ C CTG AGT TTT CCC AGC CGC CCC TCT TTG CAT 
G 3‟ 
 
D4S30 
 
LF → SS 
Forward 5‟ C ATG CAA AGA GGG TCG TCT GGG AAA ACT 
CAG G 3‟ 
Reverse 5‟ C CTG AGT TTT CCC AGA CGA CCC TCT TTG CAT 
G 3‟ 
 
Site-directed mutagenesis (SDM) was carried out using the 
Quik™Change Site-Directed Mutagenesis kit (Stratagene, USA) using 
forward and reverse primers designed for each serotype as described above.  
SDM was completed according to the protocol provided in the kit with 
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individual sample reactions containing 10ng plasmid DNA template, 125ng of 
each of the forward and reverse primers, 5µL 10x reaction buffer, 1µL dNTPs 
mix and milli-pure H2O to a final volume of 50µL. One µL of Pfu Turbo DNA 
polymerase was added to the mixture.  
Polymerase chain reaction (PCR) was performed using the Veriti 96 
Well Thermal Cycler (Applied Biosystems, USA) with an incubation profile 
as follows: one cycle at 95 ⁰C for 30 seconds, followed by 18 cycles of: 30 
seconds at 95 ⁰C, 1 minute at 55 ⁰C, and 6 minutes at 68 ⁰C. PCR products 
were incubated at 37 ⁰C in the presence of 1µL of DpnI restriction enzyme for 
one hour to digest the methylated plasmid template. The plasmids were 
transformed into DH5α competent cells as per the manufacturer‟s protocol and 
grown on LBA agar plates at 37 ⁰C overnight. Three single colonies were 
selected for each of the mutants and grown in 5ml LBA at 37 ⁰C while 
shaking at 200rpm overnight. Bacterial DNA was harvested using a QIAprep 
Spin Mini-prep kit. Mutations in DNA sequence were confirmed by nucleotide 
sequencing (First Base DNA Sequencing Service, Singapore) using the T7 
promoter.  
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Table 2.2 
Bacterial growth medium (Total composition in 1 L) 
Luria broth (LB) 25g LB broth base (Difco, USA), milli-pure H2O 
LBA 25g LB, ampicillin (Sigma-Aldrich) was added to a 
working concentration of 100μg/ml, milli-pure H2O 
LBAC 25g LB broth base, a working concentration of 
100μg/ml ampicillin, a working concentration of 
50µg/ml chloramphenicol , milli-pure H2O 
LB agar 25g LB broth base, 15g Bacto-agar, milli-pure H2O 
LBA agar 25g LB broth base, 15g Bacto-agar, 100μg/ml 
ampicillin, 50µg/ml chloramphenicol, milli-pure 
H2O 
LBAC agar 25g LB broth base. 15g Bacto-agar, 100μg/ml 
ampicillin, 50µg/ml chloramphenicol , milli-pure 
H2O 
All media were autoclaved for 20 minutes at 120 ⁰C. Antibiotics were added 
prior to use. 
 
2. 2 Protein Expression 
 
pET15b vectors encoding DENV 1-4 NS2B.G4SG4.NS3pro, WT or 
mutant sequences, were transformed into 50µL BL21-CodonPlus™ (DE3) 
RIL competent cells (Stratagene, USA) as described in the manufacturer‟s 
protocol. The cells contain resistance to chloramphenicol, so LBAC broth 
(Table 2.1) and LBAC agar was used. Single colonies, which contain 
approximately 10
8
 cells, were chosen for expansion from each transformation 
plate. Each colony was resuspended in 1ml LBAC broth.  Serial dilutions were 
prepared to 10
7
, 10
6
, and 10
5
 cells/ml. 50µL from each dilution were spread on 
LBAC plates and incubated at 37 ⁰C overnight. Colonies from each plate were 
pooled and resuspended in 5 ml LBAC broth. Each plate was further washed 
with another 5 ml LBAC. The resuspension and wash volumes were pooled 
for a total of 10 ml. To determine the cell concentration, the cell suspensions 
were diluted 1:10 and the OD600 was measured using LBAC broth as a blank. 
The cell suspension was diluted with LBAC to an OD600 of approximately 1.5 
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and 10 mL of this dilution were used to inoculate 1 L of LB in a 2 L 
Erlenmeyer flask. The culture was incubated at 37 ⁰C and shaken at 200rpm 
until it reached an OD600 of approximately 0.5.   
Recombinant protein expression was induced by the addition of 
isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.40 
mM and the cells were incubated at 16 ⁰C and shaken at 200rpm for 20 hours. 
The culture was then rapidly cooled to 4⁰C, and the cells were harvested by 
centrifugation in pre-chilled centrifuge bottles at 9,000 xg for 30 minutes at 
4⁰C. The supernatant was removed and the cell pellet was either stored at -
20⁰C or immediately resuspended in 25ml Buffer A (50 mM HEPES, 300 mM 
NaCl, pH 7.5) to prepare for cell lysis.   
 
2.3 Protein Purification 
 
Cells were passed through a French press cell disrupter at 20,000psi 
three times to lyse bacterial cells. Cells were kept on ice during interim 
periods and as the lysate was collected through the discharge valve. Cellular 
debri was removed by centrifugation at 30,000xg for 30 minutes at 4 ⁰C. 
Following centrifugation, the lysate supernatant was filtered through a 0.45μm 
syringe filter (Millipore, USA).  
The lysates were purified by Immobilized Metal Affinity 
Chromatography (IMAC) on an ÄKTA purifier (GE Healthcare, Sweden) with 
a His-Trap HP 5ml column (GE Healthcare, Sweden) equilibrated with Buffer 
A. Unbound proteins washed through the column as the NS2B47NS3pro, 
which contains an N-terminal hexa-His-Tag, bound to the Ni
+
 ions in the 
column resin. Buffer B (50 mM HEPES, 300 mM NaCl, 500 mM imidazole, 
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pH 7.5), was applied to the column using a linear gradient from 0% to 45% 
(225mM imidazole).  
1.5mL fractions were collected and small aliquots of every other 
fraction were analyzed with 12% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) using standard protocols (Sambrook and Russell, 
2001).  
The fractions which contained the most protein, and those in between 
those run on the gel, were pooled and dialyzed using Snakeskin dialysis tubing 
(10,000 Da cutoff, Pierce, USA) against 1L 20 mM Tris, 150 mM NaCl, pH 
7.5 for 36h at 4
o
C. Thrombin (1U for every 100mg protein) was included in 
the dialysis tubing. Thrombin cleaves the His-Tag from the protein constructs 
(Fig. 3.1), while dialysis removes the imidazole from the protein samples. 
The dialyzed protein sample was applied onto a 5ml HisTrap column 
equilibrated with 20 mM Tris, 150 mM NaCl, pH 7.5 and the unbound protein 
was collected . The protein was kept on ice at all points before and after 
passing through the column. The eluted protein was concentrated using a 
centrifugal filtration device (Amicon Ultracel-10K, Millipore, USA) to a 
volume of 250μL. Protein concentration was measured using a NanoDrop 
2000 spectrophotometer. Either1μg or 2μg of each samples were analyzed on 
a 12% SDS-PAGE gel to check for purity. All proteins were stored at -80 ⁰C 
in small aliquots.  
 
2.4 Protein Purification for Crystallization 
 
 The proteins were purified as described above, with the following 
amendments. After thrombin cleavage, the proteins were applied to a HiTrap 
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Q ion exchange column (GE Healthcare, Sweden) and eluted using a linear 
0.0-1.0M NaCl gradient. The proteins eluted at approximately 150mM NaCl.  
The protein elution fractions were checked for concentration and purity on a 
15% SDS-PAGE gel. Those with the highest protein concentration were 
combined and concentrated to at least 20mg/ml. Proteins were stored in small 
aliquots at -80 ⁰C. 
 
2.5 Protein Functional Characterization and Biophysical Properties 
 
2.5.1 Protease Activity Assay  
 
Protease activity assay was performed in 30µL protease assay buffer 
(50mM Tris-HCl, pH 8.5 with 20% glycerol and 1mM CHAPS) containing 
10nM protease, 20µM Bz-nKRR-AMC fluorogenic substrate (benzoyl-
norleucine-leucine-arginine-arginine-7-amino-4-methylcoumarin, Mimotopes, 
Australia).  The assay was performed in a 384-well black plate (Corning, 
USA). The reaction was initiated by the addition of the Bz-nKRR-AMC, and 
AMC release was monitored at 380nm (excitation) / 450nm (emission)  using 
an Infinite M200 spectrophotometer (Tecan, Switzerland). 
 
2.5.2 Enzyme Kinetics Assay 
 
The protease activity assay was performed at 37
o
C as described above 
in section 2.5.1 using various concentrations of Bz-nKRR-AMC substrate 
(serial dilutions between 7.8µM and 1000µM). All assays were performed in 
triplicate in black, 384-well plates (Corning, USA). Each reaction was allowed 
to proceed for 30 minutes with readings every 2 minutes. 
The amount of fluorescence for each reading was converted from 
Relative Fluorescence Units (RFU) to µM AMC (the substrate leaving group) 
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using a standard AMC curve. For each initial substrate concentration, µM 
substrate release was plotted versus time to obtain a rate for each reaction. The 
rate was then plotted against initial substrate concentration to obtain an 
enzyme saturation curve, from which both Km, the Michaelis-Menten constant, 
and Vmax, the maximum rate of proteolysis, were calculated using GraphPad 
Prism software (www.graphpad.com/prism). The kcat, measured in s
-1
, was 
calculated from Vmax by dividing by the initial enzyme concentration (10nM 
for DENV 1- 3 and 1nM for DENV 4).  
 
2.5.3 Aprotinin IC50 Assay 
 
Aprotinin inhibition was assayed in 30µl reactions containing 10nM 
protease, 20µM substrate and various concentrations of aprotinin (serial 
dilutions between 0.15 and 300nM).  Each component of the reaction was in 
protease assay buffer.10µl aprotinin mixed with 10µl protease was incubated 
at room temperature for 25 minutes prior to the addition of 10µl Bz-nKRR-
AMC substrate. All assays were performed in triplicate in black, 384-well 
plates. Inhibition was monitored by the release of fluorescence at an excitation 
wavelength of 380nm and an emission wavelength of 450nm on an Infinite 
M200 spectrophotometer. Each reaction was read immediately and after 1 
hour. IC50 values were obtained using GraphPad Prism software which fit 
calculated initial velocities to a non-linear regression curve. 
 
2.5.4 Protein Stability (Tm) Assay 
 
Fluorescence-based thermal stability experiments were performed on 
all proteins. Sample reactions of 15µg protein and 8x SYPRO®-Orange dye 
(Invitrogen, USA) were prepared to a final volume of 25µL in 20mM Tris-
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HCl, 150mM NaCl, pH 7.5. The reactions were subjected to thermal ramping 
from 15 ⁰C to 70 ⁰C at 0.5 ⁰C per minute in an iQ5 Multicolor Real-Time PCR 
Detection System (BioRad). The binding of SYPRO®-Orange was measured 
as an increase in fluorescence at an excitation wavelength of 490nm and an 
emission wavelength of 575nm. The RFU generated per reaction were 
standardized to a scale from 0 to 100 and plotted against temperature (⁰C). Tm 
was determined as the temperature at the midpoint of protein unfolding (at the 
point of inflection of the curve). Additional experiments were conducted 
which tested protein stability when bound to the aprotinin inhibitor (Sigma-
Aldrich, USA). For these experiments 15µg protein in 23µL was incubated 
with 1µL of 1mM aprotinin for 25 minutes before the addition of the 
SYPRO®-Orange dye. All assays were completed in triplicate for each 
protein, with and without the addition of aprotinin, and all were completed in 
PCR strip tubes.  
 
2.5.5 Native Gel Electrophoresis 
 
Protein samples were resolved on a native acrylamide gel (Running gel 
(12% acrylamide): 34.5% H2O, 25% 1.5M Tris-HCl (pH 8.8), 40% 
Acrylamide/Bis-acrylamide (30%/0.8% w/v), 0.005% 10% (w/v) ammonium 
persulfate (APS), 0.0007% tetramethylethylenediamine (TEMED, BioRad, 
USA). Stacking gel (4% acrylamide):  61% H2O, 25% 0.5M Tris-HCl (pH 
6.8), 13% Acrylamide/Bis-acrylamide (30%/0.8% w/v), 0.005% 10% (w/v) 
APS, 0.001% TEMED.) To prepare samples for analysis, 4x sample buffer 
(52.5% H2O, 25% 0.5M Tris-HCl (pH 6.8), 20% glycerol, 2.5% bromophenol 
blue) was added to the samples in a protein:dye ratio of 4:1. The samples were 
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vortexed briefly and centrifuged briefly in a tabletop centrifuge ( Eppendorf, 
Germany). The assay was performed in native gel running buffer (25mM Tris-
HCl, 200mM glycine) in a Mini-PROTEAN Tetra Cell (BioRad, USA). 
Electrophoresis was completed at 150V for 65 minutes, or until the loading 
dye ran off the gel. The gel was stained with 0.05% Coomassie Brilliant Blue 
Stain in gel destain (50% ethanol, 10% acetic acid, 40% H2O) for 30 minutes 
and de-stained in H2O for 1 hour.  
 
2.5.6 Dynamic Light Scattering 
 
Light scattering measurements of the DENV 2 NS3pro proteins were 
obtained using a Zetasizer Nano-S Dynamic Light Scattering 
spectrophotometer (Malvern Instruments, UK). Proteins were analyzed at a 
concentration of 2mg/ml in 20mM Tris, 150mM NaCl, pH 7.5 and were 
filtered through Ultrafree-MC 0.22µm centrifugation filter devices (Millipore, 
USA) prior to DLS. 
 
2.5.7 Protein Crystallization 
 
Protein crystallization was performed using the sitting drop method. 
Protein was mixed with an equal volume of precipitating solution (1:1 ratio) 
and incubated at 20 ⁰C in a sealed chamber containing 100µl precipitating 
solution (in collaboration with Dr. Julien Lescar, Nanyang Technological 
University). Using an automated system, approximately 900 conditions 
(Hampton Research, UK) were screened using a Hampton Research Crystal 
Screen kit to optimize crystal growth. Crystallization trays were incubated at 
both 4⁰C and 20 ⁰C. 
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2.6. Surface Plasmon Resonance Biosensing 
 
2.6.1 Immobilization of Lipid onto SPR Chip 
 
One day prior to the SPR experiments, the lipid 1-Palmitoyl-2-Oleoyl-
sn-Glyvero-3-Phosphocholine (POPC) (Avanti) was dissolved in pure 
chloroform. The solution was dried under a stream of nitrogen gas overnight. 
On the day of the experiment, the dried POPC was dissolved to a final 
concentration of 0.5mM in filtered buffer (20mM Tris-HCl (pH 7.5), 
150mMNaCl, 2mM dithiothreitol (DTT), and 5% glycerol). The solution was 
extruded 5 times through a 50nm diameter filter (Whatman, UK). Dynamic 
light scattering was performed on the POPC solution to ensure homogeneity of 
the lipsomes. The experiments were performed at 25⁰C on a Biacore 3000 
instrument (Biacore, Sweden) with an L1 sensor chip (Biacore, Sweden). 
Before each experiment, the surface of the chip was regenerated on the 
machine with an injection of 40mM n-Octyl-β-D-glucopyranoside (OG) 
(Calbiochem, USA) at 5 µL per minute for 5 minutes. Once the chip had been 
cleared and washed with buffer, 20µL of the POPC lipsome solution was 
captured at a flow rate of 2µL per minute. This was followed by an injection 
of 10mM NaOH at 50µL per minute for 1 minute to remove loosely bound 
liposomes. The surface was then washed with buffer at 5µL per minute until 
the surface stabilized.  
 
2.6.2 Lipid/Protein Binding Affinity Assay 
 
Once a steady baseline was measured by the sensor, buffer (20mM 
Tris-HCl (pH 7.5), 150mM NaCl, 5% glycerol, 2mM DTT) was injected at a 
flow rate of 5µL per minute for 10 minutes to measure the change in refractive 
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index due to an injection of buffer alone. After the surface had stabilized 
again, DENV 2 WT and mutant NS2B47NS3pro, at a concentration of 10µM, 
were injected at a flow rate of 5 µL per minute for 10 minutes. After injection 
and protein binding, the dissociation phase was monitored for 10 minutes. 
Raw sensograms were solvent corrected and normalized for lipid quantity. 
 
2.6.3 Inhibitor/Protein Binding Affinity Assay 
 
 After completion of the Lipid/Protein Binding Affinity Assay, 
aprotinin inhibitor was injected onto the SPR platform at a flow rate of 5µL 
per minute for 10 minutes. Aprotinin concentrations of 500nM and 10μM 
were tested for binding affinity. 
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3. RESULTS 
 
3.1 Mutagenesis 
 
Recombinant plasmids separately encoding all four serotypes of 
DENV NS2B47NS3pro (Li et al., 2005) were used as template and either 
double Ala or double Ser mutations were introduced to amino acid positions 
30 and 31 in NS3pro using site-directed mutagenesis (SDM). The primers 
used for SDM, in addition to the mutations introduced, are listed in Table 2.1. 
All mutations were verified by sequencing (First Base DNA Sequencing 
Service, Singapore). 
For the remainder of this study, each of the proteins will be referred to 
by a shortened name. Each name will indicate the DENV serotype and 
whether the protein is either WT or one of the mutants. For example, DENV 2 
WT NS2B47NS3pro will be referred to as D2WT, whereas the HT29-32 
double Ala mutant and double Ser mutants for the DENV 2 serotype will be 
referred to as D2A30 and D2S30, respectively. 
 
3.2 Protein Expression and Purification  
 
Single chain NS2B47NS3pro protein constructs for all four DENV 
serotypes were successfully expressed and purified. Mutant constructs, which 
contained either double Ala or double Ser amino acid substitutions at positions 
30 and 31 in NS3pro, were also generated, expressed and purified for each 
serotype.  
Protein expression and yield was monitored throughout the purification 
process. Aliquots of the protein D3S30 during the expression and purification 
process are shown in Figure 3.1 A. Of particular note, the protein quantity in 
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the whole cell lysate (Fig. 3.1 A, Lane 3) was similar in quantity in 
comparison to the protein which remained soluble after centrifugation (Fig. 
3.1 A, Lane 4). This indicates that the protein is highly soluble as most was 
retained in solution. Lane 5 represents the protein after IMAC. An example of 
the IMAC step in purification is shown in Figure 3.1, B and C. This step in the 
protein purification process is necessary to remove the His-Tagged 
NS2B47NS3pro from other proteins and molecules in the cell lysate. The 
second peak in the elution profile (Fig. 3.1 B) contains the protein of interest. 
The proteins eluted from the column when the buffer contained 150-165mM 
imidazole. Figure 3.1 C shows the relative amount of protein in each fraction 
of the elution. This information was used to choose which fractions to pool 
and use for further purification. The minor protein band located directly below 
the protein of interest, which is especially visible in Lanes 2-5 of Figure 3.1 A, 
was analyzed in a previous study. Using Western blot, the lower band was 
detected by an anti-NS3 anti-body, but not by an anti-His antibody. Therefore, 
it was presumed to be the NS2B47NS3pro without the His-Tag (Li et al., 
2005). Lane 6 in Figure 3.1 A was the protein after thrombin cleavage and 
dialysis in 20mM Tris-HCl, 150mM NaCl, pH 7.5 buffer. There was a slight 
reduction in the size of the protein. The thrombin cleaves the His-Tag from the 
protein, so the small downward shift is expected. Finally, Lane 7 contains 1.5 
µg of the final protein product. 
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Figure 3.1: Protein expression and purification profile 
A) 12% SDS-PAGE gel with protein fractions from expression and 
purification steps for the D3S30 mutant. Lane 1 contains a fraction of bacteria 
prior to induction of protein expression. Lane 2 contains a bacteria fraction 
after overnight induction of protein expression with IPTG. Lane 3 contains 
whole cell bacteria lysate. Lane 4 clarified supernatant after centrifugation to 
remove cellular debri. Lane 5 contains protein that has undergone purification 
using IMAC. Lane 6 is the protein after 36 hours thrombin cleavage and buffer 
dialysis. Lane 7 is the final, purified protein product B) IMAC elution profile 
for the mutant D1A30. The second peak contains the NS2B47NS3pro. The 
approximate fractions which were tested for protein quantity are indicated by a 
bracket. C) 12% SDS-PAGE gel with fractions from IMAC elution. 2.5μL 
from every other fraction were run on the gel to determine which contained 
the most protein. The fractions that were pooled for further purification are 
indicated by a bracket. 
 
After the purification process, the proteins were >95% pure, as judged 
by SDS-PAGE analysis, with little contaminating proteins or proteolysis. 
However, the D2 proteins showed a small amount of contamination or 
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proteolysis (Fig. 3.2). Although the size of the protein is reported as 37 kD, the 
proteins consistently run at a slightly smaller size on a 12% SDS-PAGE gel.   
 
Figure 3.2: Final protein products 
12%SDS-PAGE gel with 1.5µg each of the DENV 1-4 WT and mutant 
NS2B47NS3pro proteins after expression and purification. 
 
Between 6 and 22 mg of protein per liter of expression culture were 
obtained for DENV 1-3. Expression and purification of the D4 serotype, 
however, was difficult and resulted in a low yield of 0.5 to 0.9 mg per liter of 
expression culture. Lower yields for the D4 serotype are not unusual and are 
consistent with previous expression attempts  (Dr. Danny Doan, personal 
communication).  
Table 3.1 
Protein yield (mg/L expression culture) 
 
DENV 1 DENV 2 DENV 3 DENV 4 
WT 22.0 6.3 15.6 0.9 
A30 20.3 11.0 16.3 0.5 
S30 18.8 6.7 12.2 0.5 
 
3.3 Protein Characterization 
 
3.3.1 Enzyme Kinetics 
 
The activities of DENV 1-4 WT proteins and mutants were 
characterized using the fluorogenic peptide substrate Bz-nKRR-AMC , which 
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is efficiently cleaved by DENV 1-4 as shown in a study by Li et al (2005). 
Steady-state kinetics parameters, including the Km, kcat, and kcat/Km, were 
calculated for each of the DENV 1-3 WT and mutant proteases in this study by 
varying the Bz-nKRR-AMC substrate concentration from approximately 10 
μM to 1000μM by completing 8 serial dilutions. The DENV 4 proteases were 
measured using serial dilutions of the substrate between approximately 4 and 
500 μM. Each assay was performed in triplicate and the protein concentration 
was kept at 10nM for DENV 1-3 and 1nM for DENV 4.  
To calculate the kinetic parameters, the RFU measured from each 
reaction were converted to units of AMC, the substrate leaving group which is 
enzymatically cleaved and released by NS3pro. The amount of AMC released 
for each substrate dilution was plotted versus time to obtain a rate for each 
reaction. This rate was then plotted versus substrate concentration, which 
yielded an enzyme concentration curve. The Vmax, or maximal enzyme 
velocity, and Km, a measure of enzyme affinity, were calculated from these 
curves using GraphPad Prism software. Enzyme saturation curves for D4WT 
and mutants D4A30 and D4S30 are shown in Figure 3.3. The amount of 
fluorescence generated with regard to time and substrate concentration was 
similar for all three proteins.  
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Figure 3.3: Enzyme saturation curves for D4WT and mutants  
Enzyme saturation curves for the D4WT and mutant proteases. The curves 
show the relation between the substrate (Bz-nKRR-AMC) concentration and 
the rate (AMC released per minute). 1nM enzyme was used per reaction for 
DENV 4 and serial dilutions of substrate concentrations between 4 and 500μM 
were used to measure rate. 
 
The kinetics parameters kcat and kcat/Km were calculated from the Vmax 
and Km measurements which were obtained from the enzyme saturation 
curves. The kcat is the substrate turnover number and is calculated directly from 
the Vmax. It is the maximum number of reactions catalyzed per unit time. The 
kcat/Km is a measure of enzyme efficiency. In this study, the enzyme kinetic 
parameters, Km, kcat and kcat/Km, were measured and calculated for the WT and 
mutant proteins for all four DENV serotypes (Table 3.2).  
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Table 3.2 
Steady-state enzyme parameters 
Serotype Construct 
Km 
(µM) 
kcat 
(s
-1
) 
kcat/Km 
(M
-1
s
-1
) 
1 WT 41.0 ± 4.0 0.32 ± 0.013 7,700 ± 810 
 
A30 27.6 ± 5.2 0.10 ± 0.007 3,700 ± 740 
 
S30 35.3 ± 4.9 0.23 ± 0.013 6,600 ± 10,200 
2 WT 100.0 ± 5.5 1.55 ± 0.032 15,500 ± 910 
 
A30 95.3 ± 2.0 2.09 ± 0.020 21,900 ± 500 
 
S30 105.8 ± 8.1 1.75 ± 0.062 16,500 ± 1,400 
3 WT 65.4 ± 8.4 2.44 ± 0.123 37,300 ± 5,100 
 
A30 80.7 ± 8.1 1.00 ± 0.042 12,300 ± 1,300 
 
S30 128.5 ± 13.3 1.36 ± 0.068 10,600 ± 1,200 
4 WT 41.9 ± 1.8 3.92 ± 0.007 93,500 ± 4,000 
 
A30 43.3 ± 4.3 7.47 ± 0.032 172,500 ± 17,000 
 
S30 38.8 ± 1.9 10.10 ± 0.021 259,400 ± 12,700 
 
Within each serotype, the proteins exhibited functional similarity based 
on the kinetics parameters, suggesting that the mutations in HT29-32 do not 
substantially affect enzyme activity. With the exception of D3, the Km values, 
in which a lower number represents a higher enzyme affinity for substrate, 
were comparable between WT and mutant proteases. The Km value for the D1 
serotype ranged between 27. 1μM for D1A30 and 41.0μM for the D1WT. The 
D4 proteins exhibited similar Km values to D1, ranging between 38.8μM for 
D4S30 and 43.3μM for D4A30. The D2 mutants, however, showed less 
affinity for substrate overall and had Km values ranging from 95.3μM for the 
D2A30 mutant to 105.8μM for the D2S30 mutant. The Km for D2WT was 
between the mutant values at 100.0μM.   The Km values for D3 were less 
consistent overall and reported a broader range of Km values, from 65.4μM for 
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D3WT to 80.7μM for D3A30 and 128.5μM for D3S30. Overall, the Km values 
were higher than those published for the WT proteases by Li et al (2005), 
however, the relative affinity between serotypes remains fairly consistent. 
Like the Km values, the kcat values, which measure enzyme turnover, 
are similar between the WT and mutants for each serotype. The D1 serotype 
proteins exhibit the lowest kcat values, between 0.10 and 0.32 s
-1
. Both the D2 
and D3 proteins showed kcat values approximately between 1.0 and 2.5 s
-1
. The 
highest kcat values, but also the greatest variation in kcat within the serotype, 
occur for the D4 proteins. The D4WT protease had a kcat of 3.92s
-1
, while kcat 
for the D4A30 mutant is 7.47s
-1
 and for the D4S30 mutant is 10.10s
-1
.  In this 
case, the mutations in HT29-32 appear to increase substrate turnover. The 
values obtained for kcat in this study are nearly directly in line with those 
published for the WT proteins by Li et al (2005). The only difference is that 
the kcat values listed here are slightly higher for both D3WT and D4WT. Taken 
together, these results indicate that the mutations in HT29-32 do not greatly 
affect substrate turnover, with the possible exception of DENV 4.  
The final kinetics parameter to be calculated was kcat/Km, a measure of 
enzyme efficiency. Because kcat/Km is a function of previously measured 
values, the results are consistent with the values previously reported in this 
study. The DENV 1 proteases had the lowest enzyme efficiency, while highest 
occurs for DENV 4. This result is consistent with enzyme kinetics data 
published by Li et al (2005); although, the values in the Li study are relatively 
lower in comparison to those in this study. This result is likely because the Km 
values obtained here are higher compared to those in the study by Li et al 
(2005). In addition, the DENV 3 mutant proteins are characterized as having 
Results  | 51 
 
 
substantially reduced enzyme efficiency as compared to the WT. This 
correlates with the reported Km values for each protein.  
Taken together, these results suggest that the D1 serotype proteases 
have the lowest affinity, substrate turnover, and enzyme efficiency, while D4 
has the highest.  The mutations in HT29-32 of DENV 1, DENV 2, and DENV 
4 seem to have little effect on enzyme kinetics, however, the introduction of 
the mutations in the D3 serotype seems to considerably reduce enzyme affinity 
for substrate and thus decrease enzyme efficiency.  
 
3.3.2 Stability 
 
Each of the proteins was tested for stability using a fluorescence-based 
thermal stability assay. In addition to protein homogeneity and solubility, the 
stability of a protein is one of the greatest predictors as to whether or not a 
protein will yield crystals. The fluorescence-based thermal stability assay is a 
measure of a protein‟s ability to withstand heat before unfolding. The principle 
of the assay is to expose the proteins to steadily increasing temperatures and 
employ a hydrophobic fluoroprobe to distinguish between folded and unfolded 
proteins. The proteins are exposed to temperatures that are steadily increased 
by half-degree increments in a real-time PCR machine. When the protein is 
folded in aqueous solution, the probe is quenched. As a protein unfolds due to 
increasing temperatures, however, its hydrophobic core is exposed and the 
fluoroprobe will preferentially bind to these hydrophobic residues. Once 
bound, the probe fluoresces, producing a signal which can be detected and 
studied as a function of temperature. The melting temperature (Tm) is 
measured by this technique and is defined as the midpoint temperature of the 
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protein-unfolding transition (Ericsson et al., 2006). To analyze changes in Tm, 
the stability curves were plotted and compared for each serotype. Figure 3.4 
shows the stability assay results for D2WT and mutants. D2A30 and D2S30 
are neither stabilized nor de-stabilized by the mutations introduced into HT29-
32. Any change would be indicated by a shift in the curve either right, for 
stabilization, or left, for destabilization. Fluorescence units are reported in 
Relative Fluorescence Units (RFU).  
 
 
Figure 3.4: Thermal shift for D2WT and mutants 
15 μg of each protein were tested using the fluorescence-based thermal 
stability assay with the fluoroprobe SYPRO® Orange protein gel stain. All 
samples were completed in triplicate. The curves for the D2 mutants indicate 
that the introduced mutations neither stabilize nor de-stabilize the proteins.  
 
The Tm was measured for all WT and mutant proteases using this assay 
(Table 3.3). DENV 1, DENV 2, and DENV 4 mutant proteins retain the 
stability of the WT proteins within each serotype. The DENV 3 mutants, 
however, appear to be destabilized as their Tm is decreased by approximately 6 
⁰C. Comparing between serotypes, the DENV 2 proteins are markedly more 
stable than the other proteins, while DENV 4 is the least.  
 
 
 
Results  | 53 
 
 
Table 3.3 
Tm (⁰C) 
 
DENV 1 DENV 2 DENV 3 DENV 4 
WT 45.25 ± 0.50 53.09 ± 0.09 47.12 ± 0.14 42.79 ± 0.16 
A30 46.96 ± 0.16 54.09 ± 0.11 41.66 ± 0.72 44.63 ± 0.18 
S30 46.97 ± 0.21 53.89 ± 0.13 40.73 ± 0.66 43.89 ± 0.36 
 
Interestingly, D3A30 and D3S30 exhibited a reduced affinity for 
substrate as listed in Table 3.2 in the „Enzyme Kinetics‟ section above. 
Therefore, the DENV 3 mutants are not only de-stabilized by the introduction 
of the mutations into HT29-32, but it also appears that the kinetics results may 
correspond to this de-stabilization. In contrast, however,  the DENV 4 
proteins, which showed both high affinity and activity in terms of enzyme 
kinetics, are the least stable of all serotypes as measured by the fluorescence-
based thermal stability assay. 
In the quest for a DENV NS3pro structure which can be solved in the 
closed conformation with an inhibitor bound to the active site, the stability of 
the proteases was measured after incubation with 1µL of a 1µM aliquot of the 
known protease inhibitor, aprotinin. Aprotinin is ubiquitous protease inhibitor 
is known to bind tightly to most trypsin-like proteases, such as DENV 
NS3pro. Aprotinin binding stabilized the DENV 1-4 WT and mutant proteases 
by approximately 5⁰C. Stabilization of proteins upon ligand binding is well 
documented (Brandts and Lin, 1990; Geerlof et al., 2006), but the relative 
amount of stabilization can be compared. Because stabilization was consistent 
between WT and mutant proteases for all four serotypes, the mutations in the 
proteins do not appear to interrupt inhibitor binding.  
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3.3.3 Native Gel Electrophoresis 
 
The isoelectronic point (pI) is an indication of overall protein charge.  
The theoretical pIs for each of the proteins in this study were calculated using 
ExPASy (www.au.expasy.org) and are listed in Table 3.4. As shown, the 
theoretical pIs of the mutant proteins are calculated to remain identical to the 
WT proteins, as the amino acid substitutions (either XX → AA or XX → SS, 
where X is either I,L, or F) are charge neutral. 
Table 3.4 
Theoretical pIs 
 DENV 1 DENV 2 DENV 3 DENV 4 
WT 5.27 5.60 5.36 5.62 
A30 5.27 5.60 5.36 5.62 
S30 5.27 5.60 5.36 5.62 
 
Each of the WT NS2B47NS3pro were run on a native acrylamide gel to 
test whether the differences in the theoretical pIs could be confirmed visually. 
Native gel electrophoresis is a technique used to determine differences or 
variation in overall protein charge or conformation. Native gel electrophoresis 
is identical to standard SDS-PAGE, except no SDS is added to any component 
of the assay. Therefore, proteins retain their native conformation and are 
separated on the gel based on the intrinsic charge of the protein in relation to 
the pH of the gel running buffer. As shown in Figure 3.5 A, native gel 
electrophoresis supports the calculated theoretical pIs. D1WT and D3WT have 
similar pIs, 5.27 and 5.36 respectively, and have a comparable level of protein 
migration. D2WT and D4WT, which have slightly higher theoretical pIs in 
comparison to D1WT and D3WT, 5.60 and 5.62 respectively, also have a 
similar migration which is higher than either D1WT or D3WT. Also as 
expected, when the mutants were run alongside the WT on a native gel, there 
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was no observed change in protein migration. Based on the theoretical pIs and 
native gel mobility, these results suggest that the mutations do not cause any 
change in overall protein charge or conformation. 
 
Figure 3.5: Native gel analysis 
A) Native gel comparing each of the four DENV serotypes WT 
NS2B47NS3pro proteins.  2.5µg of each protein were loaded per well. B) 
D2WT and mutants D2A30 and D2S30 as resolved on a native gel. 2µg of 
each protein were loaded per well. 
 
 
3.3.4 Inhibitory Effect of Aprotinin 
 
The IC50 is defined as the concentration of a particular inhibitor which 
causes a 50% reduction in enzyme activity. It is a quantitative measure of the 
effectiveness of a compound to inhibit biological or biochemical function. To 
measure the IC50, NS3pro concentration was kept constant at 10nM, while 
aprotinin concentration varied between 333 and 0.15nM aprotinin using 8 
serial dilutions. The fluorogenic substrate Bz-nKRR-AMC was added at a 
final concentration of 20uM, and the fluorescence generated from each 
reaction was measured in RFU. The log of aprotinin concentration is plotted 
against the fluorescence generated in order to calculate IC50 using GraphPad 
Prism software. The inhibitor aprotinin was chosen because it is the only 
commercially available inhibitor which has been shown to inhibit flaviviral 
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proteases. An example of an IC50 curve is shown for D1WT in Figure 3.6. All 
other proteins, with the exception of D4S30 for which an IC50 curve with 
aprotinin could not be obtained, produced similar curves. 
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Figure 3.6: D1WT IC50 curve for aprotinin 
D1WT IC50 curve for aprotinin protease inhibitor. 10nM protease was 
incubated with serial dilutions between 0.15 to 300nM aprotinin 
concentration. 
 
The IC50 value for the inhibitor aprotinin is listed in Table 3.5 for each 
of the proteins. Within each serotype, the WT and mutant proteins report 
similar IC50 values, which indicate that the protease active site and inhibitor 
binding ability are not affected by mutations in HT29-32. The IC50 of DENV 2 
NS3pro bound to NS2B47, but without the G4SG4 linker, is listed at the slightly 
higher value of 65nM by Leung et al (2001). In the same study, however, the 
group reported that tethering the NS2B47 to NS3pro via the non-cleavable, 
nonapeptide linker G4SG4, resulted in a more stable complex with the same 
affinity for substrate, as measured by Km, but a much higher activity, as 
measured by kcat (Leung et al., 2001). The proteases in this study are tethered 
via the G4SG4 linker and thus are presumed to be more stable and require less 
aprotinin for inhibition than NS2B47.NS3pro constructs which are not 
tethered and expressed as a single chain.   
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Comparing IC50 between serotypes, both DENV 3 and DENV 4 
proteases require slightly higher concentrations of aprotinin to achieve the 
same level of inhibition as the DENV 1 and DENV 2 serotypes. As shown in 
previous studies, however, a different inhibitor may produce a different result 
(Li et al., 2005). The difference in IC50 and substrate specificity is likely due 
to slight variation in the amino acid sequence and structure of the proteins. 
The IC50 of the D4S30 mutant protease was not able to be measured, because 
the protein was very active and a curve could not be obtained.  DENV 4 WT 
protease is known to be the most active of all the DENV serotypes and the 
introduction of the Ser double-mutation into HT29-32 appears to increase the 
overall activity of the protease.  
 
Table 3.5 
IC50 (nM) 
 
DENV 1 DENV 2 DENV 3 DENV 4 
WT 7.70nM ± 0.77 5.74nM  ± 0.64 34.30nM ± 5.64 20.04nM ± 1.99 
A30 8.71nM ± 2.86 6.03nM ± 2.01 21.49nM ± 3.90 22.45nM ± 7.47 
S30 12.41nM ± 2.59 8.77nM ± 0.67 23.28nM ± 11.48 Not done 
 
The IC50 results, in conjunction with the results from the other protein 
characterization assays show that the mutations to either Ala or Ser in HT29-
32 in both DENV 1 and DENV 2 NS3pro have little effect. The same 
mutations in DENV 3, however, seem to de-stabilize the protein, decrease the 
activity, and require less aprotinin for inhibition in comparison to D3WT. The 
introduction of the mutations appears to disrupt the integrity of the proteins. In 
DENV 4, the introduction of the mutations increases enzyme activity, but has 
little effect on stability or inhibition for the D4A30 mutant. The D4S30 
mutant, however, is much more active than either D4WT or D4A30. Because 
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of protease‟s high activity, an IC50 value was not obtained in this study. The 
differences in characterization may be due to either sequence specific 
differences or structural variations in the proteins.  
 
3.3.5 Protein Crystallography 
 
The DENV 2 proteins were chosen to test for crystallization because 
they appeared to be altered very little by the introduction of the mutations in 
HT29-32 and because the proteins were much more stable in comparison to 
the other proteins (Fig. 3.4, Table 3.3). The structure of D2WT protein has 
also been previously reported (Erbel et al., 2006), so D2WT can be used as a 
positive control.   
Attempts were made to crystallize the D2WT protein and both the 
D2A30 and D2S30 mutants with Dr. Insaf Qureshi at Nanyang Technological 
University.  Purified proteins were screened using a kit from Hampton 
Research (USA) which tested over 900 conditions for crystallization. As 
expected, the D2WT NS2B47NS3pro formed crystals under similar conditions 
to which it was previously crystallized: 0.1M MES, 40% PEG 200 (Erbel et 
al., 2006). The crystals formed within 4 days at 20 ⁰C and were of a similar 
size and morphology as those that had been obtained previously. No protein 
crystals formed for the mutants, however. Crystallization was monitored for 
30 days.  
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Figure 3.7: Protein crystals of D2WT 
Protein crystals of D2WT grown in 0.1M MES pH 6.5, 40% PEG 200. 
 
 
3.4 Lipid Binding Characterization Using Surface Plasmon Resonance 
biosensing 
 
3.4.1 Protein/Lipid Binding Affinity 
Surface Plasmon Resonance (SPR) biosensing is a technique used to 
measure intermolecular interactions in real time. In this study, the D2WT and 
mutant proteases D2A30 and D2S30, were tested for lipid association using 
Surface Plasmon Resonance (SPR). The NS3pro proteins are believed to 
interact with membranes within an infected cell, so understanding this 
interaction is important for determining the location of the enzymes during 
DENV replication and for gaining insight into specific residues of the NS3pro. 
In a previous study by Luo et al (2010), DENV 4 NS2B18NS3 full-
length protein was also tested for lipid association using SPR. Similarly, the 
group mutated the protein at HT29-32 to two Ser residues. This mutation 
abolished protein association with the lipsome surface (Fig. 1.10). 
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Replicating all aspects of the experiment by Luo et al (2010) with the 
exception of the protein constructs, both mutants, D2A30 and D2S30, show 
reduced lipid binding in comparison to the D2WT  (Fig. 3.8). The mutant‟s 
level of binding, however, is much higher in comparison to the L30F31-
S30S31 (HT29-32 double-serine mutant in NS2B18MS3 full-length protein) as 
reported by Luo et al (Luo et al., 2010).  Whereas the double-serine mutation 
in the NS2B18NS3 full-length protein yielded almost no perceptible lipid 
binding, the same double-serine mutation in the NS2B47NS3pro shows a lipid 
binding curve, located between 150 and 750 seconds on the sensogram. The 
double-Ala mutant, D2A30, produced nearly the same level of lipid binding as 
D2S30. 
 
Figure 3.8: D2WT and mutants lipid binding SPR sensogram 
Lipid binding for D2WT, D2A30, and D2S30 was tested using SPR 
biosensing. Both mutants, D2A30 and D2S30, show reduced lipid binding in 
comparison to the D2WT protease. The results were normalized for the 
amount of lipid bound to the sensor chip. 
 
The SPR experiments were technically difficult and extremely 
sensitive to small changes in the protein storage buffer. The experiments were 
conducted in a buffer (20mM Tris-HCl, 150mM NaCL, pH 7.5) that did not 
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contain any glycerol or DTT. Both had been included in the previous 
experiments with the full-length protein by Luo et al. An unexpected 
dissociation curve, which rose back up to the peak level of binding was seen 
after the protein injection. By adding glycerol to the buffer, a result was 
produced which was more consistent with the previous results for D2WT in 
the experiments by Luo et al. and with SPR biosensing results in general (Fig. 
3.8). Glycerol is known to enhance the catalytic processing of DENV NS3pro 
and to minimize protein aggregation (Arakaki et al., 2002; Nall, 2004). The 
D2 proteins were also originally measured on different days, but without 
glycerol in the buffer. When glycerol was added to the buffer, the new set of 
D2 measurements were completed in one day. The results the second time 
were not only changed with regard to the shape of the dissociation curves, but 
also with respect to the relative amount of measured binding. Thus, SPR 
measurements comparing proteins must be completed on a single day to 
reduce variability and to ensure that the relative level of binding between 
proteins is accurate for comparison. Attempts were made to measure the level 
of lipid binding between D1WT and the two DENV 1 mutants. The 
measurements, however, were conducted on different days, and the results 
between the DENV 1WT and mutant proteins were not comparable. D4 
binding measurements were also completed, but due to differences in the 
refractive index of buffer used for storage of each protein and SPR sensitivity 
to slight variations in buffer, the results were incomparable. 
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3.4.2 Protein/Inhibitor Binding Affinity 
In addition to verifying the protein‟s ability to bind to lipid, the 
addition of aprotinin inhibitor to the NS3pro already bound to the liposome 
surface was also tested to see if the interaction could be visualized using SPR. 
The goal was to conduct an initial assessment for utilizing SPR biosensing as a 
method for measuring the binding affinity of an inhibitor for the NS3pro while 
the NS3pro is bound to the liposome. Because the protein is bound to a lipid 
surface, this model would be biologically relevant in terms of protein 
orientation and in terms of conformation when bound to the surface. Inhibitor 
binding would support the proposed orientation in the Luo model, which 
features an exposed protease active site, free to bind and cleave substrate, 
facing away from the lipid membrane. If successful, this method could be 
developed into a high throughput screen for inhibitors of DENV protease. 
An SPR sensogram with the full time course of the experiment is 
shown in Figure 3.9. Prior to every SPR measurement, an injection of buffer 
takes place. This serves as a blank for the refractive index of the buffer alone 
and is subtracted from all subsequent results. Following the buffer in the 
sensogram is D2WT binding to the liposome surface. The binding curve is 
approximately 350 RU above the baseline. This experiment was conducted 
without glycerol in the buffer, thus the dissociation following the binding 
curve for D2WT rises back up to the same level as the binding curve rather 
than dropping down to a reduced level following the protein injection (Fig. 
3.9). This result is unexpected and the addition of glycerol to the buffer 
corrects the shape of the curve. Initially, 50 μL of 500nM aprotinin was passed 
over the lipid surface with D2WT protease bound. The injection appears to 
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have the same shape as a standard buffer injection. The implication is that the 
concentration is too low to visualize any binding or that no binding occurs. 
However, when a much higher concentration of aprotinin was used, 10μM - 
the same concentration of protein was originally used for binding, a strong 
binding curve became evident. The binding curve rose approximately 130 RU 
above the baseline. Aprotinin is approximately 6kD in size, whereas the 
NS2B47NS3 proteases are 37kD. The size of the protein correlates to the 
response that can be detected using SPR biosensing. The result confirms the 
orientation of the DENV protease on a lipid surface and confirms the ability to 
visualize peptide inhibitor binding while the protease is bound to a lipid 
surface. Unfortunately, due to time constraints and a limited amount of 
prepared lipid, aprotinin binding to the liposome surface, with no protease 
present, was not tested.  
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Figure 3.9: D2WT lipid binding SPR sensogram followed by aprotinin binding 
A) Surface Plasmon Resonance sensogram showing D2WT NS2B47NS3pro 
binding affinity for a liposome surface, followed by aprotinin binding to the 
protease. Proteins and aprotinin were injected at a rate of 5μL/minute for 10 
minutes. Both were injected at concentrations of 10μM. B) SPR sensogram 
showing aprotinin binding to D2WT bound to a liposome surface. The 
injection of 500nM aprotinin appears to have the same shape as a standard 
buffer injection, whereas the higher concentration 10μM allows visualization 
of binding. Both injections were at a rate of 5μL/minute for 10 minutes. 
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4. DISCUSSION 
 
The four serotypes of DENV are genetically similar but are distinct in 
terms of antigenicity. Each is able to infect humans and to elicit an immune 
response. Upon a primary infection with a single serotype, a person is able to 
produce neutralizing antibodies which clear the virus. If the person is 
subsequently infected with a different serotype, however, ADE can occur and 
the risk of DHF or DSS is substantially increased. The occurrence of an 
immune response which aids, rather than halts, disease pathogenesis poses a 
significant challenge for the development of vaccines. To date, no vaccines or 
anti-viral compounds exist for the prevention or treatment of DENV infection, 
although several candidates are currently receiving evaluation in clinical trials.  
The DENV NS3pro is an especially promising target for designing 
anti-viral therapeutics as it is requisite for viral replication. Because the 
NS3pro of all four DENV serotypes share a high level of sequence homology, 
exploring the structure and function of all the NS3pro may lead to the 
development of a single compound which inhibits all DENV serotypes. A 
particularly valuable step in this process would be to obtain a crystal structure 
of NS3pro in a closed conformation with an inhibitor bound to the active site.  
In this study, bacterial expression and purification of chimeric single 
chain NS2B47NS3pro from all four serotypes were generated for studies on the 
protein structure and function. Directed mutations were introduced to the 
HT29-32 of all four serotypes. The HT29-32 is a hydrophobic turn on the 
protein surface and was implicated to play a role in membrane association and 
to possibly improve protein crystallization.  
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4.1 Effects of Mutations on NS3 Protease 
 
4.1.1 Biophysical Properties 
 
The double Ala and double Ser mutations (XX→AA or XX→SS) 
introduced to the central two hydrophobic residues of HT29-32 caused no 
consistent changes or shifts across all serotypes, though the mutations resulted 
in some variation in the protein biophysical properties on a serotype specific 
basis.  
In terms of enzyme activity, Km and kcat values were similar between 
WT and mutants for both the DENV 1 and DENV 2 serotypes. For the DENV 
3 mutants, however, the mutations seemed to decrease both affinity and 
efficiency, whereas efficiency, but not affinity, was increased for the DENV 4 
mutants. Because the mutations are not located within or near the protease 
substrate binding site, any change in enzyme kinetics parameters was not 
expected. However, the D3A30 reported a Km of 80.7µM compared to 65.4µM 
for D3WT. The D3S30 mutant reported a great loss in affinity as the Km was 
128.5µM, over double that of D3WT. Both DENV 3 mutants reported kcat 
values of less than half of the value for D3WT and retained only 30% of the 
enzyme efficiency of D3WT as measured by kcat/Km. A structural change in 
DENV 3 NS2B47NS3pro construct caused by the introduction of the mutations 
may be responsible for the decreased affinity and thus decreased efficiency. If 
the enzyme is less able to bind substrate, it will be less able to subsequently 
cleave the substrate and will lead to an overall decrease in turnover and 
efficiency. The DENV 3 mutants, however, retained a similar aprotinin IC50 as 
D3WT, indicating that the inhibitor is able to dock in the substrate binding site 
of the mutant with equal ability compared to the WT. For DENV 4, however, 
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the value of Km remained the same, but the mutations caused substantially 
higher substrate turnover. The enzyme efficiency is also increased, with 
kcat/Km values at nearly twice that of D4WT for D4A30 and nearly three times 
D4WT for D4S30. The increase in kcat and kcat/Km cannot be explained by a 
change in substrate affinity. The mutations in the DENV 4 protease appear to 
cause the enzymes to cleave substrate more efficiently without greatly 
affecting other biophysical properties of the protein.  
A decrease in protease activity may occur if the protein were to be de-
stabilized by the mutations and the protein integrity is disrupted. This situation 
was observed in the case of the DENV 3 mutants, where both a reduction in 
stability and activity is observed. For DENV 4, however, only a small increase 
of 1 ⁰C to 2 ⁰C in Tm was observed for its mutants. Therefore, stability cannot 
explain the increase in enzyme activity. 
 
4.1.2 Protein Crystallization 
One of the primary aims of this study was to test HT29-32 mutants of 
all four DENV serotypes for enhanced crystallization. The DENV 2 proteins 
were chosen to test for protein crystallization first, over the other serotypes, 
because the mutations had little effect on the DENV 2 protease in terms of 
biophysical properties and because the parameters for crystallization of D2WT 
are already known (Erbel et al., 2006). Also, the DENV 2 proteins, with Tm 
values of approximately 53 ⁰C to 54 ⁰C, were also 6 ⁰C to 14 ⁰C more stable 
than the other serotypes. High protein stability is a positive indicator for 
protein crystallization (Geerlof et al., 2006).When tested, D2WT formed 
protein crystals within 4 days, while the mutants formed no crystals after 30 
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days in any of 900 conditions tested. Because neither D2A30 nor D2S30 
crystallized, the hydrophobic residues in HT29-32 appear to be critical contact 
for protein packing during crystallization. Because enzymes are known to 
exhibit an increase in Tm with a ligand bound (Brandts and Lin, 1990) and 
because aprotinin was shown to substantially increase the thermal stability of 
the DENV proteases overall, crystallizing the proteins with an inhibitor still 
appears possible. Further studies, however, are needed to explore how to 
engineer DENV NS3pro for crystallization in a closed conformation. 
Using computer modeling, the theoretical crystal contacts and atomic 
interactions for both D2WT and mutants were explored. Models of the 
interactions between D2WT proteins within a crystal structure show that 
HT29-32 extends into the adjacent molecule within the crystal and that the 
bonds between atoms of the two molecules are primarily van der Waals forces. 
No hydrogen bonds exist between the structures. In the D2WT model, there 
are four interactions which are less than 4 Å (Fig. 4.1) 
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Figure 4.1: Interactions between hydrophobic turn and neighboring protein as 
in crystal formation 
Secondary structure model of two DENV 2 NS2B47NS3pro proteins as 
oriented within a protein crystal. One NS2B47NS3 is colored magenta, while 
the other is shaded gray. Hydrophobic turn residues, Ile and Leu, of the HT29-
32 are shown as sticks. The color red indicates an oxygen atom within a key 
bonding amino acid residue, while blue indicates a nitrogen atom. A close-up 
panel of the HT29-32 interaction with the adjacent protein is shown in the top 
left portion of the figure. Key residues which engage in interactions between 
the proteins and are less than 4 Å in length are indicated.  
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Figure 4.2: Interactions between hydrophobic turn HT29-32 of D2A30 and 
D2S30 proteins and neighboring protein as in crystal formation 
Secondary structure model of D2A30 and D2S30 as oriented within a protein 
crystal. One protein is colored magenta, while the other is shaded gray. 
Hydrophobic turn residues of the HT29-32 are shown as sticks. Key residues 
which engage in interactions between the D2WT proteins are shown with 
changes in atomic interaction length indicated. The color red indicates an 
oxygen atom within a key bonding amino acid residue, while blue represents a 
nitrogen atom. 
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In these models, the most notable difference between the WT and 
mutant is bond length. The bonds in the WT are all between 3.5 and 4 Å in 
length. Three of the four bonds in D2A30 are predicted to lengthen between 2 
to 5 Å. The fourth interaction, between Ala-30 and Pro-132, is only slightly 
reduced in length. Because Ala is has a much shorter side-chain that either Ile 
or Leu, the increased bond length is expected. For D2S30, the hydrophobic 
character of the amino acids is replaced by hydrophilic Ser residues. As with 
D2A30, the interaction between Ser-30 and Pro-132 is also slightly shortened, 
however, the bond between Ser-21 and Tyr-161 shows the most significant 
change in that the interaction distance between atoms is reduced to 1.7 Å. 
Changes in these lengths appear to interrupt crystal contacts and are critical for 
crystal formation.  
The DENV 2 NS3pro has been shown to require a high degree of 
homogeneity and purity in order for crystals to form (D'Arcy et al., 2006). The 
proteins in this study were purified using identical processes and dynamic 
light scattering (DLS) measurements on several samples revealed similar 
polydispersity indices (PDI) for each protein. Homogeneity and purity are, 
therefore, not likely to be contributing factors to the lack of crystal formation.  
 
4.2 Dengue 1-4 Protease Characterization 
 
Exploring the structural and functional effects of the mutations on 
NS3pro provides an opportunity to compare the same features between WT 
proteases for all DENV serotypes. The proteins varied slightly in terms of 
activity, stability, overall charge and with regard to aprotinin inhibition.  
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In a previously published study by Li et al (2005), the DENV proteases 
were compared according to their substrate affinity. One of the substrates used 
for comparison was Bz-nKRR-ACMC. The ACMC (7-amino-3-
carbamoylmethyl-4-methylcoumarin) leaving group is slightly different in 
chemical composition than AMC (7-amino-4-methylcoumarin), but the 
inhibitor is assumed to be functionally very similar since the peptide 
composition is identical. This assumption is supported by the Li study, which 
reported similar kinetics values for both Bz-nKRR-ACMC and Bz-nKRR-
AMC inhibitors for the D4WT protease.  
Individual substrate kinetics show D4WT is the most active of all 
DENV WT proteases, while DENV 1 is the least. This result is supported by 
the data published by Li et al (2005). Differences in substrate affinity and 
enzyme activity may be explained by sequence variation in the portion of 
NS2B which is believed to interact with the NS3pro substrate binding site 
during ligand binding based on homology with WNV (Erbel et al., 2006). The 
high activity and efficiency of the DENV 4 protease may also correlate to the 
poor yield listed in Table 3.1. Since the DENV 4 proteins are also the least 
stable, the combination of high activity with low stability may explain why the 
protein produced a low protein yield, since the proteases may inhibit protein 
production in bacteria or are too unstable to be produced in a quantity similar 
to the other serotypes. The DENV 4 protease may hinder either viral or 
cellular activity necessary for viral replication.  
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4.3 Dengue Virus 2 NS3 Protease Membrane Association 
 
In comparison to D2 WT,  D2A30 and D2S30 showed reduced binding 
to a liposome surface using SPR biosensing. Under the same experimental 
conditions, a double Ser mutation introduced into HT29-32 of the NS2B18NS3 
full-length  protein completely disrupted binding (Luo et al., 2010). This 
difference in observation may have resulted because the NS3 proteins used in 
this study lacked the NS3hel/NTPase domain or because the NS3pro domain 
was covalently attached to 47 amino acid residues from NS2B, whereas only 
18 residues were used in the previous binding study. The additional residues 
may interact with the liposome surface and result in a binding curve. However, 
if this were the case, D2WT and the mutants would be predicted to have 
identical binding curves as they have the same NS2B sequence. The previous 
study also used the D4 serotype, while D2 was tested in this study. Slight 
variations in the amino acid sequence and or change on the protein surface 
may be responsible for a difference in lipid binding. Finally, the area of 
NS3pro which usually faces the NS3hel in the full-length and was not 
available for surface binding in the previous study may be initiating a weak 
association with the lipid, rather than HT29-32. 
 
4.4 SPR with Lipid as a High Throughput Screen for Inhibitor Binding 
 
This study represents the first experiment testing inhibitor binding to 
DENV NS3pro, while the protein is bound to a liposome surface. The chosen 
inhibitor used in this study was aprotinin, a large, ubiquitous protease 
inhibitor. At a high concentration, a binding curve of 130 RU was clearly 
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visualized, indicating strong binding and a positive ability to test inhibitor 
binding by this method. 
This method was explored to test the potential for developing this 
technique into a HTS for peptides and small molecules that are specific for 
DENV NS3pro. When the protein is bound to a liposome surface, it gains 
biological relevance as it is believed to associate with membranes within 
infected cells. Because a new liposome surface must be generated for every 
binding experiment and because the time the liposome surface takes to 
stabilize, from a few minutes to hours, this technique can be time intensive. 
Lipid must also be prepared the day preceding the experiments. As such, the 
number of binding measurements is not only limited by time, but by the 
amount of prepared lipid. Finally, because the size of the analyte (in this case, 
aprotinin binding to DENV NS3pro) directly corresponds to the height of the 
binding curve, it may not be possible to visualize the binding of smaller 
molecules. Aprotinin is approximately 6kD in size, whereas other compounds 
would inevitably be much smaller and thus more difficult to measure. It must 
be noted, however, that it may be possible to measure these interaction with 
molecules of less than 5kD using a more sensitive Biacore machine, such as a 
the BiacoreT200.  
Rather than developing this assay into a HTS, it could be used as a 
second screen to verify hits from a different HTS. If a more sensitive SPR 
machine is used kinetics parameters may be able to be calculated directly from 
the curves and used to compare inhibitor binding. Newer SPR models also 
allow for more than one sample to be tested at one time, thus reducing the 
overall time it would take to complete the assays. Other techniques which do 
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not involve lipid binding could also be utilized to reduce the time the assays 
require. For example, cysteine coupling of DENV 2 NS2B47NS3pro 
engineered to have a single Cys residue for coupling purposes has been used 
successfully for inhibitor binding studies (Bodenreider et al., 2009). His-
Tagged proteins, preferentially at the C-terminus of the constructs, could used 
to bind the protein to a SPR chip which has been coated with antibody specific 
for His-Tag. An N-terminal His-Tag may hinder the re-organization of NS2B 
around the NS3 protease and affect subsequent inhibitor binding. A final 
benefit to completing DENV NS3pro inhibitor binding studies using SPR 
without lipid is that enzyme kinetics parameters can be measured from binding 
curves. In the case of lipid SPR, the surface is too unstable throughout the 
course of an assay to generate kinetic data. 
 
4.5 Concluding Remarks 
 
The studies presented here suggest that mutations in HT29-32 do not 
significantly change the biophysical properties of DENV 1 or DENV 2 
NS2B47NS3pro but do affect the activity of DENV 4 NS2B47NS3pro and the 
stability of DENV 3 NS2B47NS3pro. HT29-32, however, was found to be 
critical for DENV 2 NS3pro crystallization and lipid association. Further 
studies which explore the structure of the protease are needed to explain why 
the activities and stabilities of DENV 3 and DENV 4 are affected by the 
mutations, while DENV 1 and DENV 2 are not. Additional experiments into 
the overall structure and other specific amino acid residues in the protease are 
also necessary to continue progress toward a structure of DENV NS3pro 
which can be solved in the closed conformation.  
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This study represents the first observation of inhibitor binding to a 
protein which is already bound to a liposome surface. The data provided here 
suggest that inhibitor binding curves to a protein already bound are possible 
using SPR, however, the length of the experiments and the long preparation 
time are barriers to using this method as a high throughput drug or analyte 
screen. Because the height of and ability to visualize the binding curves 
depends on the size of the analyte, detection of small inhibitors may be 
challenging using. Using SPR to measure inhibitor binding while the target 
protein is bound to a liposome surface could, however, be developed as a 
second screen to verify initial hits from a different HTS. If a more sensitive 
SPR machine were used, enzyme kinetics and affinity could be measured 
quantitatively for comparison between inhibitors. A newer model SPR, such as 
Biacore T200, also would allow more samples to be tested at one time, thus 
reducing some of the time needed for this technique. Other immobilization 
techniques which do not utilize lipid should also be considered for SPR testing 
of DENV NS3pro inhibitor binding. 
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